🔗

Mappings

MONDO

MONDO:0043264 post-traumatic epilepsy

MONDO:0043264 is the post-traumatic epilepsy concept, defined as recurrent seizures causally related to craniocerebral trauma.

?

Discussions and Knowledge Gaps

3

Antiseizure prophylaxis after head injury abolishes early seizures but does nothing to the late epilepsy. Why does suppressing seizure expression during the acute phase leave epileptogenesis untouched, and what does that tell us about which node the drug is actually acting on?

KNOWLEDGE GAP OPEN pte_prophylaxis_does_not_prevent_epileptogenesis

Attached to

pathophysiology#Epileptogenesis During the Latent Period pathophysiology#Traumatic Brain Injury

This is the central negative result of the field and it has a clean mechanistic reading that the entry encodes structurally. The pivotal randomized trial showed phenytoin cutting first-week seizures from 14.2 to 3.6 percent, then no benefit at all from day eight onward, with late rates numerically higher on drug at both one and two years. That dissociation is why this entry attaches prophylaxis to the injury node with MODULATES rather than to the epileptogenesis node: the drug raises seizure threshold in an acutely injured brain, and seizure threshold is simply not the same variable as the network reorganization that produces epilepsy. Three implications follow. First, an anticonvulsant screen will never find an antiepileptogenic drug, because the two are different endpoints. Second, the finding argues against early seizures being a major causal driver of epileptogenesis, since abolishing them changes nothing downstream, though it does not exclude a small effect. Third, any genuine prevention trial has to target one of the mechanism nodes upstream, the inflammasome, barrier, glial, or plasticity arms, rather than seizure expression. The gap is that no such trial has succeeded, so the causal sufficiency of any single upstream node remains unestablished in humans.

Proposed experiments

Mechanism-targeted post-traumatic epilepsy prevention trial

exp_pte_mechanism_targeted_prevention_trial

A randomized prevention trial in high-risk traumatic brain injury patients using an agent directed at an upstream mechanism node rather than at seizure threshold, such as an IL-1 receptor antagonist or an mTOR inhibitor, with late unprovoked seizures over at least two years as the primary endpoint.

Decision criterion

A reduction in late unprovoked seizures without a corresponding anticonvulsant effect would establish that the targeted node is causally necessary for epileptogenesis in humans and would separate antiepileptogenesis from anticonvulsant action as endpoints.

Test whether early seizures causally contribute to later epilepsy

exp_pte_early_seizure_causal_contribution

Pooled or individual-participant analysis of prophylaxis trials asking whether patients whose early seizures were successfully suppressed differ in late epilepsy risk from those who had breakthrough early seizures, adjusted for injury severity.

Decision criterion

Equivalent late risk regardless of early-seizure suppression would confirm early seizures as a severity marker rather than a causal step and would justify removing them from causal models entirely.

Show evidence (5 references)

PMID:2115976 SUPPORT Human Clinical

"Between day 8 and the end of year 1, 21.5 percent of the phenytoin group and 15.7 percent of the placebo group had seizures; at the end of year 2, the rates were 27.5 percent and 21.1 percent, respectively"

The primary negative finding this discussion is built on: no late benefit despite a large early effect in the same trial and population.

PMID:2115976 SUPPORT Human Clinical

"This lack of a late effect could not be attributed to differential mortality, low phenytoin levels, or treatment of some early"

The trialists explicitly excluded the obvious artefactual explanations, which is what makes the negative result mechanistically informative rather than merely inconclusive.

PMID:41187576 SUPPORT Other

"Short-term antiseizure prophylaxis reduces early provoked seizures, but no interventions prevent late unprovoked seizures or PTE."

Confirms that the dissociation still stands in current practice and is not an artefact of one older trial.

+ 2 more references

Post-traumatic epilepsy has the one thing every other epilepsy lacks, a dated initiating insult and an identifiable at-risk population, yet no prevention trial has succeeded. Is the missing ingredient a biomarker that identifies who is actually undergoing epileptogenesis?

KNOWLEDGE GAP OPEN pte_no_validated_epileptogenesis_biomarker

Attached to

pathophysiology#Epileptogenesis During the Latent Period

Most patients with traumatic brain injury never develop epilepsy, so a prevention trial enrolling on injury severity alone dilutes any true effect into a population that was mostly never going to convert. Even after severe injury the standardized incidence ratio of 17 corresponds to a minority of patients converting. That forces either impractically large trials or long follow-up, and it means a genuinely effective agent could fail for statistical rather than biological reasons. Candidate enrichment markers exist across several modalities, including neuroimaging, EEG signatures, circulating cytokines, and microRNAs, but none is validated for the purpose. There is a second, subtler problem: the latent period is defined by the absence of seizures, so it is currently a diagnosis of exclusion made retrospectively once seizures appear. Without a positive marker there is no way to confirm that a treated patient was ever undergoing epileptogenesis, which makes a negative trial uninterpretable.

Proposed experiments

Prospective multimodal biomarker validation cohort

exp_pte_prospective_biomarker_validation

A prospective cohort of patients with moderate to severe traumatic brain injury with serial imaging, EEG, and blood sampling from the acute phase onward, followed for at least five years, testing whether any single or combined marker predicts conversion to late unprovoked seizures with enough discrimination to enrich a trial.

Decision criterion

A marker or panel achieving sufficient positive predictive value to reduce required trial size by a meaningful factor would unblock prevention trials; failure of all candidates would indicate that enrichment must come from injury phenotyping instead.

Search for a positive marker of ongoing epileptogenesis

exp_pte_latent_period_positive_marker

Test whether any candidate marker changes dynamically during the latent period in converters but not non-converters, so that epileptogenesis can be identified while it is happening rather than inferred after the first seizure.

Decision criterion

A marker that tracks the process rather than the eventual outcome would make the latent period a positively defined state and would allow treatment response to be measured before seizures occur.

Show evidence (2 references)

PMID:41187576 SUPPORT Other

"Predictive biomarkers (neuroimaging, EEG, cytokines, microRNAs) are essential for risk stratification in prophylactic trials."

States the biomarker requirement and enumerates the candidate modalities, none of which is yet validated.

PMID:9414327 SUPPORT Human Clinical

"The standardized incidence ratio was 1.5 (95 percent confidence interval, 1.0 to 2.2) after mild injuries but with no increase over the expected number after five years, 2.9 (95 percent confidence interval, 1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence interval, 12.3 to..."

Quantifies why enrichment is necessary: even the highest-risk severity stratum converts at a rate that leaves most enrolled patients unable to contribute an event.

Several agents reduce seizure burden in rodent models of post-traumatic epilepsy, yet none has prevented epilepsy in humans. Is that a failure of the compounds, of trial design, or of the models themselves?

HUMAN MODEL MISMATCH OPEN pte_preclinical_to_human_translation_failure

Attached to

pathophysiology#Neuroinflammation and Inflammasome Activation pathophysiology#Epileptogenesis During the Latent Period

The candidate antiepileptogenic agents most often named, IL-1 receptor antagonists, mTOR inhibitors, and glutamate modulators such as ceftriaxone, rest on preclinical data showing reduced seizure burden. The mismatch is recorded as a human-model problem rather than a knowledge gap because the evidence exists and is positive; what is unestablished is whether it transfers. Several structural differences are candidates. Rodent models compress a latent period that in humans can run for years into weeks, so a treatment window that looks adequate in a mouse may be wrong by an order of magnitude in a patient. Model injuries are stereotyped and delivered to young healthy animals, whereas human traumatic brain injury is heterogeneous in mechanism, location, and severity, and its highest-risk group includes patients over 65. Most importantly, preclinical endpoints are usually seizure burden or frequency, which is an anticonvulsant readout, not the binary conversion-to-epilepsy endpoint a human prevention trial must use. Given that the field already knows anticonvulsant action dissociates from antiepileptogenesis in this disorder, a preclinical seizure-burden reduction may be measuring precisely the wrong thing.

Proposed experiments

Realign preclinical endpoints to conversion rather than burden

exp_pte_model_endpoint_alignment

Evaluate candidate antiepileptogenic agents in animal models using proportion of animals developing spontaneous recurrent seizures as the primary endpoint, with treatment withdrawn well before assessment so that residual anticonvulsant action cannot mask the result.

Decision criterion

Agents that reduce conversion rate after washout are genuinely antiepileptogenic candidates; agents that only reduce seizure burden on drug are anticonvulsants and should not enter prevention trials.

Correspondence of model injury to high-risk human injury phenotypes

exp_pte_model_human_injury_correspondence

Systematic comparison of the histopathological and imaging features of standard rodent post-traumatic epilepsy models against the human injury features that actually carry risk, namely contusion with subdural haematoma, penetrating injury, and older age.

Decision criterion

Poor correspondence, particularly on the lesion types that dominate human risk, would indicate the models are testing a different disease and would justify developing models built around those features.

Show evidence (3 references)

PMID:41187576 SUPPORT Other

"Promising repurposed agents include IL-1 receptor antagonists (anakinra), mTOR inhibitors (rapamycin), and glutamate modulators (ceftriaxone), with preclinical data showing reduced seizure burden."

Names the candidate agents and, critically, identifies the supporting evidence as preclinical and the endpoint as seizure burden, which is the mismatch this discussion records.

PMID:35302046 SUPPORT Other

"Differences in injury patterns, latency period, and biomarkers are outlined in the context of animal model validation"

Identifies injury pattern and latency differences as explicit model validation concerns, which are two of the structural mismatches named in the rationale.

PMID:35302046 SUPPORT Other

"There is currently no approved treatment that can prevent onset of spontaneous seizures associated with brain injury"

Confirms the human-side half of the mismatch, that no preventive treatment has translated despite the preclinical signal.

⚙

Pathophysiology

8

Traumatic Brain Injury

Mechanical injury to the brain is the initiating and dated event. Risk of subsequent epilepsy scales steeply with severity: after mild injury the excess risk is small and disappears within five years, whereas after severe injury with contusion, subdural haematoma, skull fracture, or prolonged loss of consciousness it rises many-fold and persists for decades.

Downstream

Early Provoked Seizures A branch that leads to acute symptomatic seizures rather than to epilepsy. It is modelled explicitly because the entry's central argument is that this branch and the epileptogenesis branch dissociate pharmacologically.

Blood-Brain Barrier Disruption and Albumin Extravasation

Neuroinflammation and Inflammasome Activation

GABAergic Interneuron Loss

Show evidence (2 references)

PMID:9414327 SUPPORT Human Clinical

"The standardized incidence ratio was 1.5 (95 percent confidence interval, 1.0 to 2.2) after mild injuries but with no increase over the expected number after five years, 2.9 (95 percent confidence interval, 1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence interval, 12.3 to..."

The population-based cohort that quantifies the severity-graded dose response between the injury and later unprovoked seizures, which is the causal claim this node makes.

PMID:9414327 SUPPORT Human Clinical

"significant risk factors for later seizures were brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia for more than one day, and an age of 65 years or older"

Identifies the specific injury features that carry risk, supporting the structural-damage reading of this node rather than a generic concussion effect.

Early Provoked Seizures

Acute symptomatic seizures in the first seven days after injury. This is a terminal node, not a step toward epilepsy, and that is the point: it is modelled as a separate branch off the injury rather than upstream of epileptogenesis, because abolishing it pharmacologically leaves late epilepsy unchanged. Whether it contributes causally at all, or is purely a marker of injury severity, is recorded as a discussion.

Show evidence (2 references)

PMID:41187576 SUPPORT Other

"Short-term antiseizure prophylaxis reduces early provoked seizures, but no interventions prevent late unprovoked seizures or PTE."

States the dissociation between this node and the epileptogenesis branch, which is the reason it is modelled separately.

PMID:41187576 SUPPORT Other

"PTE develops via epileptogenesis-a latent, multifactorial process distinct from acute seizure triggers"

Explicitly separates acute seizure triggering from epileptogenesis, which is the modelling decision this node encodes.

Blood-Brain Barrier Disruption and Albumin Extravasation

Trauma breaches the blood-brain barrier, allowing serum albumin into the neuropil where it is taken up by astrocytes and triggers TGF-beta receptor signalling. The downstream consequence is loss of astrocytic potassium and glutamate buffering capacity, which lowers the seizure threshold of the surrounding tissue. Barrier dysfunction after trauma is long-lasting rather than transient, which is what makes it a plausible driver of a process unfolding over months.

maintenance of blood-brain barrier GO:0035633 ↓ DECREASED

Downstream

Reactive Astrogliosis and Impaired Glutamate Homeostasis

Show evidence (6 references)

PMID:41187576 SUPPORT Other

"involving chronic neuroinflammation (e.g., IL-1β, NLRP3 pathways), blood-brain barrier dysfunction, maladaptive gliosis with glutamate dysregulation, and aberrant plasticity"

Names blood-brain barrier dysfunction as a component of post-traumatic epileptogenesis alongside the other nodes modelled here.

PMID:17121744 SUPPORT Model Organism

"We demonstrate that direct brain exposure to serum albumin is associated with albumin uptake into astrocytes, which is mediated by transforming growth factor beta receptors (TGF-betaRs). This uptake is followed by down regulation of inward-rectifying potassium (Kir 4.1) channels in astrocytes,..."

The direct evidence for the albumin-to-astrocyte-TGF-beta-receptor chain and the loss of potassium buffering asserted in this node's description. It supplies each step: uptake into astrocytes, receptor mediation, Kir4.1 downregulation, and the resulting failure of extracellular potassium buffering.

PMID:17121744 SUPPORT Model Organism

"Blocking TGF-betaR in vivo reduces the likelihood of epileptogenesis in albumin-exposed brains to 29.3%"

Interventional evidence running the other way: blocking the receptor reduces epileptogenesis, which supports a causal rather than merely associative reading of this node.

+ 3 more references

Neuroinflammation and Inflammasome Activation

Injury activates inflammasome signalling, with IL-1 beta and the NLRP3 pathway as the best-characterized axis. The resulting chronic inflammatory state is one of the leading candidate links between the acute injury and the later emergence of seizures, and it is the target of the most-discussed repurposing candidate, the IL-1 receptor antagonist anakinra.

inflammasome-mediated signaling pathway GO:0141084 ↑ INCREASED

Downstream

Reactive Astrogliosis and Impaired Glutamate Homeostasis

Epileptogenesis During the Latent Period Inflammasome signalling is consistently associated with epileptogenesis, but the causal chain from a cytokine signal to a reorganized epileptic network is not resolved, so the edge is recorded as indirect with unknown intermediates.

Show evidence (2 references)

PMID:39014496 SUPPORT Other

"Inflammasome signaling is one of the major components of the neuroinflammatory response, which is increasingly being explored for its contribution to the epileptogenic mechanisms and a novel therapeutic target against epilepsy."

Establishes inflammasome signalling as a candidate epileptogenic mechanism and therapeutic target, which is what this node asserts.

PMID:41187576 SUPPORT Other

"Promising repurposed agents include IL-1 receptor antagonists (anakinra), mTOR inhibitors (rapamycin), and glutamate modulators (ceftriaxone), with preclinical data showing reduced seizure burden."

Identifies the IL-1 axis as a druggable node, supporting its mechanistic role while making clear the supporting data are preclinical.

Reactive Astrogliosis and Impaired Glutamate Homeostasis

Astrocytes become reactive, upregulating glial fibrillary acidic protein and crystallin alpha-B, and their normal housekeeping fails: glutamate clearance is impaired and calcium signalling becomes aberrant. Because astrocytes are what keep extracellular glutamate low between synapses, losing that function shifts the tissue toward excitation independently of any change in the neurons themselves. These changes have been identified in contused human tissue, not only in animal models.

astrocyte CL:0000127 ⚠ ABNORMAL

astrocyte activation GO:0048143 ↑ INCREASED

Downstream

Epileptogenesis During the Latent Period

Show evidence (2 references)

PMID:39826185 SUPPORT Human Clinical

"Increased expression of glial fibrillary acidic protein and crystallin alpha-B in reactive astrocytes identified in contused human tissue suggests their involvement in exacerbating epileptogenic circuits."

Human contused cortical tissue evidence for reactive astrogliosis in post-traumatic epileptogenesis, which anchors this node in human material rather than in animal models alone.

PMID:39826185 SUPPORT Human Clinical

"we detail the role of reactive astrogliosis, elucidating how dysregulated astrocytic functions, including impaired glutamate homeostasis and aberrant calcium signaling, contribute to an environment conducive to seizure activity"

States the specific astrocytic dysfunctions, impaired glutamate handling and aberrant calcium signalling, that this node models.

GABAergic Interneuron Loss

Inhibitory interneurons are selectively vulnerable after trauma. Loss of subpopulations defined by the calcium-binding proteins parvalbumin, calretinin, and calbindin removes feed-forward and feedback inhibition from the surviving circuit, producing an excitation-inhibition imbalance that does not require any increase in excitatory drive to be epileptogenic.

GABAergic interneuron CL:0000617 ↓ DECREASED

gamma-aminobutyric acid signaling pathway GO:0007214 ↓ DECREASED

Downstream

Epileptogenesis During the Latent Period

Show evidence (1 reference)

PMID:39826185 SUPPORT Human Clinical

"We analyzed alterations in interneuron populations, specifically subtypes expressing the calcium-binding proteins parvalbumin, calretinin, and calbindin, and their association with an increased risk of epileptogenesis after TBI."

Names the specific interneuron subpopulations whose loss is associated with post-traumatic epileptogenesis, which is the claim of this node.

Epileptogenesis During the Latent Period

The convergence node. Over weeks to years the injured network reorganizes: aberrant plasticity, including mTOR-dependent circuit remodelling, combines with the inflammatory, glial, and inhibitory changes upstream to convert a normal brain into one that generates spontaneous hypersynchronous activity. This is the process, not the seizures, and it is the only therapeutic window in which the disease could in principle be prevented rather than suppressed. No treatment is currently known to act on it.

Downstream

Late Unprovoked Seizures

Show evidence (2 references)

PMID:35302046 SUPPORT Other

"Post-traumatic epileptogenesis is an enduring process by which a normal brain exhibits hypersynchronous excitability after a head injury incident."

Defines post-traumatic epileptogenesis as an enduring process converting normal brain to hypersynchronous, which is exactly what this node represents.

PMID:41187576 SUPPORT Other

"PTE develops via epileptogenesis-a latent, multifactorial process distinct from acute seizure triggers"

States that epileptogenesis is a latent process distinct from acute seizure triggering, which is the separation this entry is built around.

Late Unprovoked Seizures

Recurrent spontaneous seizures, usually focal in onset and correlating with the site of injury, constituting post-traumatic epilepsy proper. They are frequently drug-resistant.

Show evidence (1 reference)

PMID:39014496 SUPPORT Other

"Post-traumatic epilepsy (PTE) is one of the most debilitating consequences of traumatic brain injury (TBI) and is one of the most drug-resistant forms of epilepsy."

Establishes the clinical character of the terminal node, including its characteristic drug resistance.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

2

Nervous System 1

Late Unprovoked Focal Seizures Focal-onset seizure HP:0007359

Show evidence (2 references)

PMID:9414327 SUPPORT Human Clinical

"The increased risk of seizures after traumatic brain injury varies greatly according to the severity of the injury and the time since the injury."

Supports that unprovoked seizures follow traumatic brain injury and that the risk is severity- and time-dependent. Marked PARTIAL because this cohort counted unprovoked seizures without reporting semiology, so it does not itself support the focal-onset binding; see the description for the basis of that. No frequency band is asserted, because no cited source quantifies what proportion of post-traumatic seizures are focal in onset.

PMID:35302046 SUPPORT Other

"many cases of PTE are refractory to antiseizure medications"

Supports the drug-resistance characterization included in this phenotype description.

Other 1

Drug-Resistant Epilepsy Refractory drug response HP:0020174

Show evidence (1 reference)

PMID:39014496 SUPPORT Other

"Post-traumatic epilepsy (PTE) is one of the most debilitating consequences of traumatic brain injury (TBI) and is one of the most drug-resistant forms of epilepsy."

States the drug resistance directly. No frequency band is asserted because the sources characterize the resistance qualitatively rather than reporting a proportion.

💊

Medical Actions

2

Short-Term Antiseizure Prophylaxis

Action: Pharmacotherapy NCIT:C15986

Agent: phenytoin CHEBI:8107 levetiracetam CHEBI:6437

Phenytoin or, in current practice, levetiracetam given for approximately seven days after severe traumatic brain injury. This reliably reduces early provoked seizures. It does not reduce late unprovoked seizures, and in the pivotal randomized trial the late-seizure rates were numerically higher in the treated arm. The correct reading is that this is seizure suppression during the acute phase, not disease prevention, and it should not be continued in the hope of preventing epilepsy.

Mechanism Target:

MODULATES Traumatic Brain Injury — Prophylaxis acts on acute seizure expression in the injured brain during the first week. It is deliberately NOT modelled as targeting the epileptogenesis node, because the pivotal trial showed no effect on late seizures.

Show evidence (4 references)

PMID:2115976 SUPPORT Human Clinical

"Between drug loading and day 7, 3.6 percent of the patients assigned to phenytoin had seizures, as compared with 14.2 percent of patients assigned to placebo"

Establishes efficacy against early provoked seizures, the one benefit this treatment has.

PMID:2115976 REFUTE Human Clinical

"Between day 8 and the end of year 1, 21.5 percent of the phenytoin group and 15.7 percent of the placebo group had seizures; at the end of year 2, the rates were 27.5 percent and 21.1 percent, respectively"

Recorded as REFUTE for the disease-prevention claim. Late seizure rates were if anything higher on phenytoin, which is why prophylaxis must not be presented as antiepileptogenic.

PMID:38316735 SUPPORT Human Clinical

"If used, we suggest LEV over PHT/fPHT (weak recommendation, very low quality of evidence) for a short duration"

The current guideline basis for using levetiracetam rather than phenytoin, and for keeping the course short. Marked PARTIAL because the recommendation is explicitly weak and rests on very low-quality evidence.

+ 1 more reference

Antiseizure Medication for Established Post-Traumatic Epilepsy

Action: Pharmacotherapy NCIT:C15986

Agent: levetiracetam CHEBI:6437

Once late unprovoked seizures are established, treatment follows standard focal-epilepsy practice. Response is often poor, and post-traumatic epilepsy is among the more drug-resistant focal epilepsies.

Mechanism Target:

INHIBITS Late Unprovoked Seizures — Symptomatic suppression of the terminal seizure phenotype, targeting seizure expression rather than any upstream mechanism node.

Show evidence (1 reference)

PMID:35302046 SUPPORT Other

"many cases of PTE are refractory to antiseizure medications"

Records the limited efficacy of symptomatic treatment. Marked PARTIAL because it qualifies rather than endorses the intervention.

🌍

Environmental Factors

1

Traumatic Brain Injury

Head trauma is the necessary environmental cause of this disorder, and it is what makes post-traumatic epilepsy unusual among epilepsies: the exposure is discrete, dated, and in principle preventable. Risk is graded by severity rather than binary. Mild injury confers only a small excess risk that disappears within five years; moderate injury roughly triples it; and severe injury, defined by loss of consciousness or amnesia beyond 24 hours, subdural haematoma, or brain contusion, raises it seventeen-fold and keeps it elevated for decades. Age over 65 at the time of injury is an independent risk factor. Penetrating injury is conventionally held to carry higher risk than closed head injury, but no source cited here demonstrates that, so it is not asserted as a modelled risk factor.

Show evidence (2 references)

PMID:9414327 SUPPORT Human Clinical

"Injuries were classified as mild (loss of consciousness or amnesia lasting less than 30 minutes), moderate (loss of consciousness for 30 minutes to 24 hours or a skull fracture), or severe (loss of consciousness or amnesia for more than 24 hours, subdural hematoma, or brain contusion)."

Gives the operational severity definitions on which the graded exposure response in this entry rests.

PMID:9414327 SUPPORT Human Clinical

"The increased risk of seizures after traumatic brain injury varies greatly according to the severity of the injury and the time since the injury."

States the severity dependence and time dependence of the exposure effect, which is the substance of this environmental record.

🔬

Diagnosis

2

Electroencephalography

EEG is used both acutely, to detect non-convulsive seizures in a sedated or unconscious patient after severe injury, and later to characterize an established epilepsy. Its role in the latent period is aspirational rather than established: EEG signatures are among the candidate biomarkers of ongoing epileptogenesis but none is validated for that purpose, which is the subject of one of this entry's discussions.

Electroencephalography NCIT:C38054

Results: Focal epileptiform abnormality corresponding to the injury site in established post-traumatic epilepsy; no validated latent-period signature.

Show evidence (1 reference)

PMID:41187576 SUPPORT Other

"Predictive biomarkers (neuroimaging, EEG, cytokines, microRNAs) are essential for risk stratification in prophylactic trials."

Names EEG among the candidate predictive modalities. Marked PARTIAL because it establishes EEG as a candidate rather than a validated diagnostic for epileptogenesis.

Brain imaging

Imaging establishes the structural substrate and, critically, the injury features that carry epilepsy risk: contusion, subdural haematoma, and skull fracture. It is therefore doing risk stratification as much as diagnosis. Contrast-enhanced imaging can also demonstrate the blood-brain barrier leakage modelled upstream, which persisted for months in the animal and human work cited here.

Magnetic Resonance Imaging NCIT:C16809

Results: Contusion, subdural haematoma, or other structural injury; persistent barrier leakage on contrast-enhanced sequences.

Show evidence (2 references)

PMID:9414327 SUPPORT Human Clinical

"significant risk factors for later seizures were brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia for more than one day, and an age of 65 years or older"

Establishes that the imaging findings themselves carry the risk information, which is why imaging is a risk-stratification step here and not only a structural survey.

PMID:32919030 SUPPORT Model Organism

"MRI indicated persistent Gd leakage in the impacted cortex and thalamus of variable severity in all rats with TBI which correlated with fluorescein extravasation."

Demonstrates that contrast-enhanced MRI can detect the persistent barrier leakage modelled in the pathophysiology section. Rat data; the same study confirmed chronic barrier dysfunction in human PTE autopsy tissue.

📈

Progression

3

Early provoked seizures

Age: First seven days after injury

Acute symptomatic seizures occurring within the first week. These are provoked events, not epilepsy, and they are the only part of the disorder that responds to prophylaxis. Whether they are themselves epileptogenic or merely a marker of severe injury is unresolved and is recorded as a discussion.

Show evidence (1 reference)

PMID:2115976 SUPPORT Human Clinical

"Between drug loading and day 7, 3.6 percent of the patients assigned to phenytoin had seizures, as compared with 14.2 percent of patients assigned to placebo"

Quantifies the early-seizure phase and demonstrates that it is pharmacologically suppressible, which is what distinguishes it from the late phase.

Latent period

Age: Weeks to years after injury

A clinically silent interval during which epileptogenesis proceeds. Its length is highly variable, and the absence of a validated biomarker to confirm that epileptogenesis is underway in a given patient is the principal obstacle to running a prevention trial.

Show evidence (1 reference)

PMID:41187576 SUPPORT Other

"Predictive biomarkers (neuroimaging, EEG, cytokines, microRNAs) are essential for risk stratification in prophylactic trials."

States the biomarker requirement that defines the practical problem of this phase.

Established post-traumatic epilepsy

Age: Months to decades after injury

Chronic recurrent unprovoked seizures, frequently drug-resistant, with substantial neuropsychiatric comorbidity. Risk after severe injury remains elevated for decades rather than resolving.

Show evidence (2 references)

PMID:35302046 SUPPORT Other

"The goal of epilepsy research is to identify new therapeutic strategies that can prevent PTE development or interrupt the epileptogenic process and relieve associated neuropsychiatric comorbidities."

Evidences the neuropsychiatric comorbidity asserted in this phase, and shows that relieving it is treated as a goal of the field alongside preventing the epilepsy itself rather than as an incidental concern.

PMID:9414327 SUPPORT Human Clinical

"The increased risk of seizures after traumatic brain injury varies greatly according to the severity of the injury and the time since the injury."

Supports the time-varying, severity-dependent character of the chronic phase.

📊

Prevalence

1

Olmsted County, Minnesota population-based TBI cohort (1935-1984)

Unknown Unknown

This record captures relative rather than absolute occurrence. The population-based cohort reports a standardized incidence ratio of 3.1 for unprovoked seizures across all traumatic brain injury severities, rising to 17.0 after severe injury. Because these are ratios against expected population rates rather than a rate in the general population, no rate_per_100000 and no prevalence class are asserted here; the absolute burden depends entirely on the background incidence of head injury in the population of interest.

Show evidence (1 reference)

PMID:9414327 SUPPORT Human Clinical

"The overall standardized incidence ratio was 3.1 (95 percent confidence interval, 2.5 to 3.8)."

Gives the overall standardized incidence ratio for unprovoked seizures after traumatic brain injury in a defined population.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Post-Traumatic Epilepsy:

Early Provoked Post-Traumatic Seizures

Overlapping Features Acute symptomatic seizures within seven days of injury. These are not epilepsy and do not by themselves establish the diagnosis, but they are routinely conflated with it, including in older literature. Distinguishing them matters because only these respond to prophylaxis.

Distinguishing Features

Onset within the first seven days after the injury.
Provoked by the acute injury rather than by an established epileptic network.
Suppressible by short-term antiseizure prophylaxis.

Show evidence (1 reference)

PMID:41187576 SUPPORT Other

"Short-term antiseizure prophylaxis reduces early provoked seizures, but no interventions prevent late unprovoked seizures or PTE."

States the pharmacological dissociation that is the practical basis for separating these two entities.

Psychogenic Non-Epileptic Seizures

Overlapping Features Common after traumatic brain injury and frequently comorbid with genuine post-traumatic epilepsy, which makes the distinction a recurring clinical problem rather than an academic one. Video-EEG is required to separate them.

Distinguishing Features

No ictal EEG correlate during a captured typical event.
Semiology that does not conform to a recognized seizure pattern.

Chronic Traumatic Encephalopathy

Overlapping Features Also a delayed consequence of head trauma, but a neurodegenerative tauopathy associated with repetitive impacts, defined neuropathologically and presenting with cognitive and behavioural decline rather than with recurrent seizures as the cardinal feature. dismech carries a separate entry.

Distinguishing Features

Repetitive rather than single severe head impacts.
Progressive cognitive and behavioural decline as the leading feature.
Neuropathological diagnosis based on perivascular tau pathology.

🔬

Clinical Trials

2

NCT01463033

A pilot study of levetiracetam given acutely after traumatic brain injury, designed to establish safety, tolerability, pharmacokinetics, and feasibility, with two-year follow-up for pilot data on post-traumatic epilepsy. It is the empirical expression of the hope that a newer agent with preclinical antiepileptogenic activity might succeed where phenytoin failed.

Target Phenotypes: Focal-onset seizure HP:0007359

Show evidence (2 references)

clinicaltrials:NCT01463033 SUPPORT Human Clinical

"Past attempts at preventing epilepsy by treatment with older antiepileptic drugs have been unsuccessful."

The trial's own stated premise, which is this entry's prophylaxis paradox restated as a rationale for further study.

clinicaltrials:NCT01463033 SUPPORT Human Clinical

"Levetiracetam is a novel AED with potent antiepileptogenic properties in animal models of epilepsy."

Records the preclinical rationale. Marked PARTIAL because antiepileptogenic activity in animal models is precisely the claim that this entry's human-model mismatch discussion treats as unestablished for humans.

NCT01048138 COMPLETED

A placebo-controlled randomized double-blind trial of biperiden, a muscarinic antagonist, as a disease-modifying agent after traumatic brain injury. It targets a mechanism rather than seizure threshold, which is the strategy this entry's prophylaxis discussion argues is required, and it is therefore the closest thing to a direct test of that argument. It completed, and it was negative. Analysis showed no evidence of benefit for either the incidence of post-traumatic epilepsy or mortality. The paper also reports more late post-traumatic seizures in the biperiden arm. The figure is a count-regression coefficient on the log scale, a difference in the logs of expected counts of 2.03 with a 95 percent confidence interval of 0.912 to 3.1597; the null for such a coefficient is zero, not one, so the interval excludes it and the reported p below 0.001 is consistent. The estimate also survives adjustment for the on-scene Glasgow Coma Scale score, falling only to 1.857. The reason not to read that as drug harm is allocation imbalance, and the authors say so themselves: the biperiden arm tended toward more severe injuries by on-scene GCS and had more frequent bilateral brain lesions, both established risk factors for post-traumatic epilepsy. Their own conclusion names the unbalanced distribution of those variables as the reason larger studies are needed. The trial was additionally halted early for the COVID-19 pandemic and under-enrolled against its planned 132 participants. Taken together it is a mechanism-targeted intervention, tested as the prophylaxis discussion prescribes, that failed to show benefit in an underpowered and imbalanced sample.

Target Phenotypes: Focal-onset seizure HP:0007359

Show evidence (6 references)

clinicaltrials:NCT01048138 SUPPORT Human Clinical

"There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy."

States the absence of any established antiepileptogenic agent, which is the gap this entry's discussions are built around, from a trial registration rather than a review.

PMID:39175759 REFUTE Human Clinical

"Data analysis indicated lack of evidence of biperiden for either, the incidence of post-traumatic epilepsy (2.6, 95%CI, 0.65-10.57; p = 0.170) or the mortality rate (1.57, 95%CI, 0.73-3.38; p = 0.248)."

The published negative result. Recorded as REFUTE so the entry states plainly that the mechanism-targeted strategy has been tried in humans and did not work, rather than presenting the trial as a live prospect.

PMID:39175759 REFUTE Human Clinical

"The frequency of late post-traumatic seizures was higher for biperiden group (2.03, 95%CI = 0.912-3.1597; p <0.001)."

A statistically significant excess of late seizures in the biperiden arm. The 2.03 is a difference in the logs of expected counts, so the relevant null is zero rather than one and the interval excludes it; the estimate holds at 1.857 after adjustment for the on-scene Glasgow Coma Scale score. It is recorded as a real finding but not as demonstrated drug harm, because the arms were imbalanced on injury severity in the direction that would produce exactly this result.

+ 3 more references

{ }

Source YAML

click to show

name: Post-Traumatic Epilepsy
creation_date: "2026-08-05T00:00:00Z"
category: Complex
description: >-
  Post-traumatic epilepsy is recurrent unprovoked seizures caused by traumatic
  brain injury. It is the archetypal acquired epilepsy and the one place in
  epileptology where the initiating insult is dated to the day, which makes it
  the natural testbed for antiepileptogenesis. A latent period of weeks to years
  separates the injury from the first spontaneous seizure, and during that
  interval blood-brain barrier breakdown, inflammasome-driven neuroinflammation,
  reactive astrogliosis with impaired glutamate handling, GABAergic interneuron
  loss, and aberrant synaptic plasticity together convert normal cortex into an
  epileptic network. Risk scales steeply with injury severity. Short-term
  antiseizure prophylaxis suppresses early provoked seizures but has never been
  shown to prevent the epilepsy itself.
parents:
  - Epilepsy
  - Neurological Disease
synonyms:
  - PTE
  - epilepsies, post-traumatic
  - traumatic epilepsy
disease_term:
  preferred_term: post-traumatic epilepsy
  term:
    id: MONDO:0043264
    label: post-traumatic epilepsy
mappings:
  mondo_mappings:
    - term:
        id: MONDO:0043264
        label: post-traumatic epilepsy
      mapping_predicate: skos:exactMatch
      mapping_source: MONDO
      mapping_justification: >-
        MONDO:0043264 is the post-traumatic epilepsy concept, defined as
        recurrent seizures causally related to craniocerebral trauma.
references:
  - reference: PMID:35302046
    title: >-
      Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
      Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
  - reference: PMID:41187576
    title: >-
      The path to post-traumatic epilepsy: A review of emerging biomarkers and
      therapeutic targets.
notes: >-
  Scope and terminology note. The clinically important distinction in this
  disorder is between early provoked seizures, occurring within the first seven
  days after injury and treated as acute symptomatic events, and late unprovoked
  seizures, which constitute post-traumatic epilepsy proper. This entry models
  the latter. The distinction is not pedantic: the one intervention that works in
  this disorder works only on the former, which is the central tension the
  discussions record. Concussive convulsions occurring immediately at impact are
  non-epileptic phenomena and are out of scope.

  Drug resistance is modelled on the terminal pathophysiology node and on a
  dedicated Refractory drug response phenotype rather than by reusing the
  focal-seizure term with a severity qualifier.

  Scope note on breadth. This entry concentrates on the epileptogenesis
  mechanism and the early-versus-late seizure dissociation. Dimensions that
  remain uncurated are flagged here rather than silently omitted: structural
  sequelae such as gliosis and hippocampal atrophy, surgical and neuromodulatory
  options for drug-resistant cases, mortality outcomes, and candidate genetic
  modifiers such as IL1B. These are follow-up work, not judgements that they are
  unimportant.
pathophysiology:
  - name: Traumatic Brain Injury
    biological_scale: TISSUE
    description: >-
      Mechanical injury to the brain is the initiating and dated event. Risk of
      subsequent epilepsy scales steeply with severity: after mild injury the
      excess risk is small and disappears within five years, whereas after severe
      injury with contusion, subdural haematoma, skull fracture, or prolonged
      loss of consciousness it rises many-fold and persists for decades.
    downstream:
      - target: Early Provoked Seizures
        causal_link_type: DIRECT
        description: >-
          A branch that leads to acute symptomatic seizures rather than to
          epilepsy. It is modelled explicitly because the entry's central
          argument is that this branch and the epileptogenesis branch dissociate
          pharmacologically.
        evidence:
          - reference: PMID:2115976
            reference_title: >-
              A randomized, double-blind study of phenytoin for the prevention of
              post-traumatic seizures.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              Between drug loading and day 7, 3.6 percent of the patients
              assigned to phenytoin had seizures, as compared with 14.2 percent
              of patients assigned to placebo
            explanation: >-
              Establishes that early seizures follow the injury and are
              pharmacologically suppressible, which is what distinguishes this
              branch from the epileptogenesis branch.
      - target: Blood-Brain Barrier Disruption and Albumin Extravasation
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:41187576
            reference_title: >-
              The path to post-traumatic epilepsy: A review of emerging
              biomarkers and therapeutic targets.
            supports: SUPPORT
            evidence_source: OTHER
            snippet: >-
              involving chronic neuroinflammation (e.g., IL-1β, NLRP3 pathways),
              blood-brain barrier dysfunction, maladaptive gliosis with glutamate
              dysregulation, and aberrant plasticity
            explanation: >-
              Places blood-brain barrier dysfunction downstream of the injury as
              a component of post-traumatic epileptogenesis.
      - target: Neuroinflammation and Inflammasome Activation
        causal_link_type: DIRECT
      - target: GABAergic Interneuron Loss
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:39826185
            reference_title: >-
              Post-traumatic epilepsy: Insights from human cortical contused
              tissue.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              We analyzed alterations in interneuron populations, specifically
              subtypes expressing the calcium-binding proteins parvalbumin,
              calretinin, and calbindin, and their association with an increased
              risk of epileptogenesis after TBI.
            explanation: >-
              Links interneuron alterations directly to traumatic brain injury
              and to subsequent epileptogenesis risk, which is this edge.
    evidence:
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The standardized incidence ratio was 1.5 (95 percent confidence
          interval, 1.0 to 2.2) after mild injuries but with no increase over the
          expected number after five years, 2.9 (95 percent confidence interval,
          1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence
          interval, 12.3 to 23.6) after severe injuries.
        explanation: >-
          The population-based cohort that quantifies the severity-graded dose
          response between the injury and later unprovoked seizures, which is the
          causal claim this node makes.
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          significant risk factors for later seizures were brain contusion with
          subdural hematoma, skull fracture, loss of consciousness or amnesia for
          more than one day, and an age of 65 years or older
        explanation: >-
          Identifies the specific injury features that carry risk, supporting the
          structural-damage reading of this node rather than a generic concussion
          effect.
  - name: Early Provoked Seizures
    biological_scale: ORGANISM
    description: >-
      Acute symptomatic seizures in the first seven days after injury. This is a
      terminal node, not a step toward epilepsy, and that is the point: it is
      modelled as a separate branch off the injury rather than upstream of
      epileptogenesis, because abolishing it pharmacologically leaves late
      epilepsy unchanged. Whether it contributes causally at all, or is purely a
      marker of injury severity, is recorded as a discussion.
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Short-term antiseizure prophylaxis reduces early provoked seizures, but
          no interventions prevent late unprovoked seizures or PTE.
        explanation: >-
          States the dissociation between this node and the epileptogenesis
          branch, which is the reason it is modelled separately.
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          PTE develops via epileptogenesis-a latent, multifactorial process
          distinct from acute seizure triggers
        explanation: >-
          Explicitly separates acute seizure triggering from epileptogenesis,
          which is the modelling decision this node encodes.
  - name: Blood-Brain Barrier Disruption and Albumin Extravasation
    biological_scale: CELLULAR
    description: >-
      Trauma breaches the blood-brain barrier, allowing serum albumin into the
      neuropil where it is taken up by astrocytes and triggers TGF-beta receptor
      signalling. The downstream consequence is loss of astrocytic potassium and
      glutamate buffering capacity, which lowers the seizure threshold of the
      surrounding tissue. Barrier dysfunction after trauma is long-lasting rather
      than transient, which is what makes it a plausible driver of a process
      unfolding over months.
    biological_processes:
      - preferred_term: maintenance of blood-brain barrier
        term:
          id: GO:0035633
          label: maintenance of blood-brain barrier
        modifier: DECREASED
    downstream:
      - target: Reactive Astrogliosis and Impaired Glutamate Homeostasis
        causal_link_type: DIRECT
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          involving chronic neuroinflammation (e.g., IL-1β, NLRP3 pathways),
          blood-brain barrier dysfunction, maladaptive gliosis with glutamate
          dysregulation, and aberrant plasticity
        explanation: >-
          Names blood-brain barrier dysfunction as a component of post-traumatic
          epileptogenesis alongside the other nodes modelled here.
      - reference: PMID:17121744
        reference_title: >-
          TGF-beta receptor-mediated albumin uptake into astrocytes is involved
          in neocortical epileptogenesis.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          We demonstrate that direct brain exposure to serum albumin is
          associated with albumin uptake into astrocytes, which is mediated by
          transforming growth factor beta receptors (TGF-betaRs). This uptake is
          followed by down regulation of inward-rectifying potassium (Kir 4.1)
          channels in astrocytes, resulting in reduced buffering of extracellular
          potassium.
        explanation: >-
          The direct evidence for the albumin-to-astrocyte-TGF-beta-receptor
          chain and the loss of potassium buffering asserted in this node's
          description. It supplies each step: uptake into astrocytes, receptor
          mediation, Kir4.1 downregulation, and the resulting failure of
          extracellular potassium buffering.
      - reference: PMID:17121744
        reference_title: >-
          TGF-beta receptor-mediated albumin uptake into astrocytes is involved
          in neocortical epileptogenesis.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Blocking TGF-betaR in vivo reduces the likelihood of epileptogenesis in
          albumin-exposed brains to 29.3%
        explanation: >-
          Interventional evidence running the other way: blocking the receptor
          reduces epileptogenesis, which supports a causal rather than merely
          associative reading of this node.
      - reference: PMID:25836421
        reference_title: >-
          Albumin induces excitatory synaptogenesis through astrocytic
          TGF-beta/ALK5 signaling in a model of acquired epilepsy following
          blood-brain barrier dysfunction.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Here we demonstrate in vitro and in vivo that activation of the
          astrocytic ALK5/TGF-β-pathway induces excitatory, but not inhibitory,
          synaptogenesis that precedes the appearance of seizures.
        explanation: >-
          Extends the mechanism past potassium buffering to excitatory
          synaptogenesis, the structural change that could sustain a chronically
          epileptic network rather than a transient threshold shift. The finding
          is established in both cultured cells and live animals, and the
          synaptogenesis precedes seizure onset, which places it inside the
          latent period rather than after it.
      - reference: PMID:32919030
        reference_title: >-
          Long-lasting blood-brain barrier dysfunction and neuroinflammation
          after traumatic brain injury.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Analysis of human autopsy tissue indicated that similar to the animal
          model, chronic BBB dysfunction was also evident in the perilesional
          cortex and thalamus of patients with PTE, characterized by presence of
          albumin, iron deposits and calcifications as well as markers of
          neuroinflammation, including reactive astrocytes, microglia and
          monocytes.
        explanation: >-
          Human autopsy tissue from post-traumatic epilepsy patients showing
          chronic barrier dysfunction with albumin extravasation and
          neuroinflammation, which is precisely the mechanism this node asserts
          and anchors it in human material rather than in the rat model alone.
      - reference: PMID:32919030
        reference_title: >-
          Long-lasting blood-brain barrier dysfunction and neuroinflammation
          after traumatic brain injury.
        supports: REFUTE
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Unlike expected, we did not find any association between increased
          Gd-leakage or neuroinflammation with seizure susceptibility at 11
          months post-TBI.
        explanation: >-
          Carried deliberately as disconfirming evidence. In the same rat study
          that established the barrier dysfunction is long-lasting, the degree of
          leakage did not correlate with seizure susceptibility. This node is
          therefore modelled as a persistent post-traumatic change plausibly
          contributing to epileptogenesis, not as a quantitatively sufficient
          driver of it.
  - name: Neuroinflammation and Inflammasome Activation
    biological_scale: CELLULAR
    description: >-
      Injury activates inflammasome signalling, with IL-1 beta and the NLRP3
      pathway as the best-characterized axis. The resulting chronic inflammatory
      state is one of the leading candidate links between the acute injury and
      the later emergence of seizures, and it is the target of the most-discussed
      repurposing candidate, the IL-1 receptor antagonist anakinra.
    biological_processes:
      - preferred_term: inflammasome-mediated signaling pathway
        term:
          id: GO:0141084
          label: inflammasome-mediated signaling pathway
        modifier: INCREASED
    downstream:
      - target: Reactive Astrogliosis and Impaired Glutamate Homeostasis
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Epileptogenesis During the Latent Period
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
        description: >-
          Inflammasome signalling is consistently associated with
          epileptogenesis, but the causal chain from a cytokine signal to a
          reorganized epileptic network is not resolved, so the edge is recorded
          as indirect with unknown intermediates.
    evidence:
      - reference: PMID:39014496
        reference_title: >-
          Inflammasomes at the crossroads of traumatic brain injury and
          post-traumatic epilepsy.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Inflammasome signaling is one of the major components of the
          neuroinflammatory response, which is increasingly being explored for
          its contribution to the epileptogenic mechanisms and a novel
          therapeutic target against epilepsy.
        explanation: >-
          Establishes inflammasome signalling as a candidate epileptogenic
          mechanism and therapeutic target, which is what this node asserts.
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Promising repurposed agents include IL-1 receptor antagonists
          (anakinra), mTOR inhibitors (rapamycin), and glutamate modulators
          (ceftriaxone), with preclinical data showing reduced seizure burden.
        explanation: >-
          Identifies the IL-1 axis as a druggable node, supporting its
          mechanistic role while making clear the supporting data are preclinical.
  - name: Reactive Astrogliosis and Impaired Glutamate Homeostasis
    biological_scale: CELLULAR
    description: >-
      Astrocytes become reactive, upregulating glial fibrillary acidic protein
      and crystallin alpha-B, and their normal housekeeping fails: glutamate
      clearance is impaired and calcium signalling becomes aberrant. Because
      astrocytes are what keep extracellular glutamate low between synapses,
      losing that function shifts the tissue toward excitation independently of
      any change in the neurons themselves. These changes have been identified in
      contused human tissue, not only in animal models.
    cell_types:
      - preferred_term: astrocyte
        term:
          id: CL:0000127
          label: astrocyte
        modifier: ABNORMAL
    biological_processes:
      - preferred_term: astrocyte activation
        term:
          id: GO:0048143
          label: astrocyte activation
        modifier: INCREASED
    downstream:
      - target: Epileptogenesis During the Latent Period
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:39826185
            reference_title: >-
              Post-traumatic epilepsy: Insights from human cortical contused
              tissue.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              This review discusses the critical role of GABAergic interneurons
              and reactive astrogliosis in the pathophysiology of post-traumatic
              epilepsy, integrating findings from our research group within the
              traumatic brain injury context with recent literature to highlight
              the impact of excitation-inhibition imbalance.
            explanation: >-
              Places both the interneuron and astroglial arms upstream of the
              excitation-inhibition imbalance that constitutes epileptogenesis,
              supporting these convergent edges.
    evidence:
      - reference: PMID:39826185
        reference_title: >-
          Post-traumatic epilepsy: Insights from human cortical contused tissue.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Increased expression of glial fibrillary acidic protein and crystallin
          alpha-B in reactive astrocytes identified in contused human tissue
          suggests their involvement in exacerbating epileptogenic circuits.
        explanation: >-
          Human contused cortical tissue evidence for reactive astrogliosis in
          post-traumatic epileptogenesis, which anchors this node in human
          material rather than in animal models alone.
      - reference: PMID:39826185
        reference_title: >-
          Post-traumatic epilepsy: Insights from human cortical contused tissue.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          we detail the role of reactive astrogliosis, elucidating how
          dysregulated astrocytic functions, including impaired glutamate
          homeostasis and aberrant calcium signaling, contribute to an
          environment conducive to seizure activity
        explanation: >-
          States the specific astrocytic dysfunctions, impaired glutamate
          handling and aberrant calcium signalling, that this node models.
  - name: GABAergic Interneuron Loss
    biological_scale: CELLULAR
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
    description: >-
      Inhibitory interneurons are selectively vulnerable after trauma. Loss of
      subpopulations defined by the calcium-binding proteins parvalbumin,
      calretinin, and calbindin removes feed-forward and feedback inhibition from
      the surviving circuit, producing an excitation-inhibition imbalance that
      does not require any increase in excitatory drive to be epileptogenic.
    cell_types:
      - preferred_term: GABAergic interneuron
        term:
          id: CL:0000617
          label: GABAergic neuron
        modifier: DECREASED
    biological_processes:
      - preferred_term: gamma-aminobutyric acid signaling pathway
        term:
          id: GO:0007214
          label: gamma-aminobutyric acid signaling pathway
        modifier: DECREASED
    downstream:
      - target: Epileptogenesis During the Latent Period
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:39826185
            reference_title: >-
              Post-traumatic epilepsy: Insights from human cortical contused
              tissue.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              This review discusses the critical role of GABAergic interneurons
              and reactive astrogliosis in the pathophysiology of post-traumatic
              epilepsy, integrating findings from our research group within the
              traumatic brain injury context with recent literature to highlight
              the impact of excitation-inhibition imbalance.
            explanation: >-
              Places both the interneuron and astroglial arms upstream of the
              excitation-inhibition imbalance that constitutes epileptogenesis,
              supporting these convergent edges.
    evidence:
      - reference: PMID:39826185
        reference_title: >-
          Post-traumatic epilepsy: Insights from human cortical contused tissue.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We analyzed alterations in interneuron populations, specifically
          subtypes expressing the calcium-binding proteins parvalbumin,
          calretinin, and calbindin, and their association with an increased risk
          of epileptogenesis after TBI.
        explanation: >-
          Names the specific interneuron subpopulations whose loss is associated
          with post-traumatic epileptogenesis, which is the claim of this node.
  - name: Epileptogenesis During the Latent Period
    biological_scale: TISSUE
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Seizure Generation and Epileptogenesis"
    description: >-
      The convergence node. Over weeks to years the injured network reorganizes:
      aberrant plasticity, including mTOR-dependent circuit remodelling, combines
      with the inflammatory, glial, and inhibitory changes upstream to convert a
      normal brain into one that generates spontaneous hypersynchronous activity.
      This is the process, not the seizures, and it is the only therapeutic
      window in which the disease could in principle be prevented rather than
      suppressed. No treatment is currently known to act on it.
    downstream:
      - target: Late Unprovoked Seizures
        causal_link_type: DIRECT
    evidence:
      - reference: PMID:35302046
        reference_title: >-
          Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
          Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Post-traumatic epileptogenesis is an enduring process by which a normal
          brain exhibits hypersynchronous excitability after a head injury
          incident.
        explanation: >-
          Defines post-traumatic epileptogenesis as an enduring process converting
          normal brain to hypersynchronous, which is exactly what this node
          represents.
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          PTE develops via epileptogenesis-a latent, multifactorial process
          distinct from acute seizure triggers
        explanation: >-
          States that epileptogenesis is a latent process distinct from acute
          seizure triggering, which is the separation this entry is built around.
  - name: Late Unprovoked Seizures
    biological_scale: ORGANISM
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
    description: >-
      Recurrent spontaneous seizures, usually focal in onset and correlating with
      the site of injury, constituting post-traumatic epilepsy proper. They are
      frequently drug-resistant.
    evidence:
      - reference: PMID:39014496
        reference_title: >-
          Inflammasomes at the crossroads of traumatic brain injury and
          post-traumatic epilepsy.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Post-traumatic epilepsy (PTE) is one of the most debilitating
          consequences of traumatic brain injury (TBI) and is one of the most
          drug-resistant forms of epilepsy.
        explanation: >-
          Establishes the clinical character of the terminal node, including its
          characteristic drug resistance.
phenotypes:
  - name: Late Unprovoked Focal Seizures
    category: Neurologic
    description: >-
      Recurrent unprovoked seizures beginning more than seven days after the
      injury. These define the disorder, as distinct from the early provoked
      seizures of the first week, and they are frequently refractory to
      antiseizure medication.

      The focal-onset binding rests on the disease definition rather than on a
      measured series: MONDO:0043264, following its MeSH source, states that the
      majority of seizures have a focal onset correlating clinically with the
      site of brain injury. None of the sources cited in this entry reports
      seizure semiology, so no proportion is asserted and no frequency band is
      given.
    phenotype_term:
      preferred_term: Focal-onset seizure
      term:
        id: HP:0007359
        label: Focal-onset seizure
    evidence:
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The increased risk of seizures after traumatic brain injury varies
          greatly according to the severity of the injury and the time since the
          injury.
        explanation: >-
          Supports that unprovoked seizures follow traumatic brain injury and
          that the risk is severity- and time-dependent. Marked PARTIAL because
          this cohort counted unprovoked seizures without reporting semiology, so
          it does not itself support the focal-onset binding; see the description
          for the basis of that. No frequency band is asserted, because no cited
          source quantifies what proportion of post-traumatic seizures are
          focal in onset.
      - reference: PMID:35302046
        reference_title: >-
          Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
          Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          many cases of PTE are refractory to antiseizure medications
        explanation: >-
          Supports the drug-resistance characterization included in this
          phenotype description.
  - name: Drug-Resistant Epilepsy
    category: Neurologic
    description: >-
      A substantial fraction of established post-traumatic epilepsy responds
      poorly to antiseizure medication, which is a major driver of long-term
      disability and the reason the field's stated goal is prevention rather
      than suppression.
    phenotype_term:
      preferred_term: Refractory drug response
      term:
        id: HP:0020174
        label: Refractory drug response
    evidence:
      - reference: PMID:39014496
        reference_title: >-
          Inflammasomes at the crossroads of traumatic brain injury and
          post-traumatic epilepsy.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Post-traumatic epilepsy (PTE) is one of the most debilitating
          consequences of traumatic brain injury (TBI) and is one of the most
          drug-resistant forms of epilepsy.
        explanation: >-
          States the drug resistance directly. No frequency band is asserted
          because the sources characterize the resistance qualitatively rather
          than reporting a proportion.
environmental:
  - name: Traumatic Brain Injury
    presence: PRESENT
    description: >-
      Head trauma is the necessary environmental cause of this disorder, and it
      is what makes post-traumatic epilepsy unusual among epilepsies: the
      exposure is discrete, dated, and in principle preventable. Risk is graded by
      severity rather than binary. Mild injury confers only a small excess risk
      that disappears within five years; moderate injury roughly triples it; and
      severe injury, defined by loss of consciousness or amnesia beyond 24 hours,
      subdural haematoma, or brain contusion, raises it seventeen-fold and keeps
      it elevated for decades. Age over 65 at the time of injury is an
      independent risk factor. Penetrating injury is conventionally held to carry
      higher risk than closed head injury, but no source cited here demonstrates
      that, so it is not asserted as a modelled risk factor.
    effect: >-
      Increases risk of later unprovoked seizures in proportion to injury
      severity, with the excess risk persisting for decades after severe injury.
    evidence:
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Injuries were classified as mild (loss of consciousness or amnesia
          lasting less than 30 minutes), moderate (loss of consciousness for 30
          minutes to 24 hours or a skull fracture), or severe (loss of
          consciousness or amnesia for more than 24 hours, subdural hematoma, or
          brain contusion).
        explanation: >-
          Gives the operational severity definitions on which the graded exposure
          response in this entry rests.
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The increased risk of seizures after traumatic brain injury varies
          greatly according to the severity of the injury and the time since the
          injury.
        explanation: >-
          States the severity dependence and time dependence of the exposure
          effect, which is the substance of this environmental record.
prevalence:
  - population: Olmsted County, Minnesota population-based TBI cohort (1935-1984)
    measure_type: UNKNOWN
    prevalence_class: UNKNOWN
    notes: >-
      This record captures relative rather than absolute occurrence. The
      population-based cohort reports a standardized incidence ratio of 3.1 for
      unprovoked seizures across all traumatic brain injury severities, rising to
      17.0 after severe injury. Because these are ratios against expected
      population rates rather than a rate in the general population, no
      rate_per_100000 and no prevalence class are asserted here; the absolute
      burden depends entirely on the background incidence of head injury in the
      population of interest.
    evidence:
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The overall standardized incidence ratio was 3.1 (95 percent confidence
          interval, 2.5 to 3.8).
        explanation: >-
          Gives the overall standardized incidence ratio for unprovoked seizures
          after traumatic brain injury in a defined population.
progression:
  - phase: Early provoked seizures
    age_range: First seven days after injury
    notes: >-
      Acute symptomatic seizures occurring within the first week. These are
      provoked events, not epilepsy, and they are the only part of the disorder
      that responds to prophylaxis. Whether they are themselves epileptogenic or
      merely a marker of severe injury is unresolved and is recorded as a
      discussion.
    evidence:
      - reference: PMID:2115976
        reference_title: >-
          A randomized, double-blind study of phenytoin for the prevention of
          post-traumatic seizures.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Between drug loading and day 7, 3.6 percent of the patients assigned to
          phenytoin had seizures, as compared with 14.2 percent of patients
          assigned to placebo
        explanation: >-
          Quantifies the early-seizure phase and demonstrates that it is
          pharmacologically suppressible, which is what distinguishes it from the
          late phase.
  - phase: Latent period
    age_range: Weeks to years after injury
    notes: >-
      A clinically silent interval during which epileptogenesis proceeds. Its
      length is highly variable, and the absence of a validated biomarker to
      confirm that epileptogenesis is underway in a given patient is the
      principal obstacle to running a prevention trial.
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Predictive biomarkers (neuroimaging, EEG, cytokines, microRNAs) are
          essential for risk stratification in prophylactic trials.
        explanation: >-
          States the biomarker requirement that defines the practical problem of
          this phase.
  - phase: Established post-traumatic epilepsy
    age_range: Months to decades after injury
    notes: >-
      Chronic recurrent unprovoked seizures, frequently drug-resistant, with
      substantial neuropsychiatric comorbidity. Risk after severe injury remains
      elevated for decades rather than resolving.
    evidence:
      - reference: PMID:35302046
        reference_title: >-
          Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
          Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The goal of epilepsy research is to identify new therapeutic strategies
          that can prevent PTE development or interrupt the epileptogenic process
          and relieve associated neuropsychiatric comorbidities.
        explanation: >-
          Evidences the neuropsychiatric comorbidity asserted in this phase, and
          shows that relieving it is treated as a goal of the field alongside
          preventing the epilepsy itself rather than as an incidental concern.
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The increased risk of seizures after traumatic brain injury varies
          greatly according to the severity of the injury and the time since the
          injury.
        explanation: >-
          Supports the time-varying, severity-dependent character of the chronic
          phase.
treatments:
  - name: Short-Term Antiseizure Prophylaxis
    description: >-
      Phenytoin or, in current practice, levetiracetam given for approximately
      seven days after severe traumatic brain injury. This reliably reduces early
      provoked seizures. It does not reduce late unprovoked seizures, and in the
      pivotal randomized trial the late-seizure rates were numerically higher in
      the treated arm. The correct reading is that this is seizure suppression
      during the acute phase, not disease prevention, and it should not be
      continued in the hope of preventing epilepsy.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: phenytoin
          term:
            id: CHEBI:8107
            label: phenytoin
        - preferred_term: levetiracetam
          term:
            id: CHEBI:6437
            label: levetiracetam
    target_mechanisms:
      - target: Traumatic Brain Injury
        treatment_effect: MODULATES
        description: >-
          Prophylaxis acts on acute seizure expression in the injured brain
          during the first week. It is deliberately NOT modelled as targeting the
          epileptogenesis node, because the pivotal trial showed no effect on
          late seizures.
    evidence:
      - reference: PMID:2115976
        reference_title: >-
          A randomized, double-blind study of phenytoin for the prevention of
          post-traumatic seizures.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Between drug loading and day 7, 3.6 percent of the patients assigned to
          phenytoin had seizures, as compared with 14.2 percent of patients
          assigned to placebo
        explanation: >-
          Establishes efficacy against early provoked seizures, the one benefit
          this treatment has.
      - reference: PMID:2115976
        reference_title: >-
          A randomized, double-blind study of phenytoin for the prevention of
          post-traumatic seizures.
        supports: REFUTE
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Between day 8 and the end of year 1, 21.5 percent of the phenytoin
          group and 15.7 percent of the placebo group had seizures; at the end of
          year 2, the rates were 27.5 percent and 21.1 percent, respectively
        explanation: >-
          Recorded as REFUTE for the disease-prevention claim. Late seizure rates
          were if anything higher on phenytoin, which is why prophylaxis must not
          be presented as antiepileptogenic.
      - reference: PMID:38316735
        reference_title: >-
          Guidelines for Seizure Prophylaxis in Adults Hospitalized with
          Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline
          for Health Care Professionals from the Neurocritical Care Society.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          If used, we suggest LEV over PHT/fPHT (weak recommendation, very low
          quality of evidence) for a short duration
        explanation: >-
          The current guideline basis for using levetiracetam rather than
          phenytoin, and for keeping the course short. Marked PARTIAL because the
          recommendation is explicitly weak and rests on very low-quality
          evidence.
      - reference: PMID:38316735
        reference_title: >-
          Guidelines for Seizure Prophylaxis in Adults Hospitalized with
          Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline
          for Health Care Professionals from the Neurocritical Care Society.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          There were no significant differences in early or late seizures with
          longer versus shorter ASM use, though cognitive outcomes and adverse
          events appear worse with protracted use.
        explanation: >-
          Directly supports this entry's central thesis from the treatment side:
          extending prophylaxis buys no additional seizure protection, early or
          late, and costs cognition and tolerability. Prolonging the drug in hope
          of preventing epilepsy is therefore harm without benefit.
  - name: Antiseizure Medication for Established Post-Traumatic Epilepsy
    description: >-
      Once late unprovoked seizures are established, treatment follows standard
      focal-epilepsy practice. Response is often poor, and post-traumatic
      epilepsy is among the more drug-resistant focal epilepsies.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: levetiracetam
          term:
            id: CHEBI:6437
            label: levetiracetam
    target_mechanisms:
      - target: Late Unprovoked Seizures
        treatment_effect: INHIBITS
        description: >-
          Symptomatic suppression of the terminal seizure phenotype, targeting
          seizure expression rather than any upstream mechanism node.
    evidence:
      - reference: PMID:35302046
        reference_title: >-
          Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
          Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          many cases of PTE are refractory to antiseizure medications
        explanation: >-
          Records the limited efficacy of symptomatic treatment. Marked PARTIAL
          because it qualifies rather than endorses the intervention.
diagnosis:
  - name: Electroencephalography
    description: >-
      EEG is used both acutely, to detect non-convulsive seizures in a sedated or
      unconscious patient after severe injury, and later to characterize an
      established epilepsy. Its role in the latent period is aspirational rather
      than established: EEG signatures are among the candidate biomarkers of
      ongoing epileptogenesis but none is validated for that purpose, which is
      the subject of one of this entry's discussions.
    diagnosis_term:
      preferred_term: Electroencephalography
      term:
        id: NCIT:C38054
        label: Electroencephalography
    results: >-
      Focal epileptiform abnormality corresponding to the injury site in
      established post-traumatic epilepsy; no validated latent-period signature.
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Predictive biomarkers (neuroimaging, EEG, cytokines, microRNAs) are
          essential for risk stratification in prophylactic trials.
        explanation: >-
          Names EEG among the candidate predictive modalities. Marked PARTIAL
          because it establishes EEG as a candidate rather than a validated
          diagnostic for epileptogenesis.
  - name: Brain imaging
    description: >-
      Imaging establishes the structural substrate and, critically, the injury
      features that carry epilepsy risk: contusion, subdural haematoma, and skull
      fracture. It is therefore doing risk stratification as much as diagnosis.
      Contrast-enhanced imaging can also demonstrate the blood-brain barrier
      leakage modelled upstream, which persisted for months in the animal and
      human work cited here.
    diagnosis_term:
      preferred_term: Magnetic Resonance Imaging
      term:
        id: NCIT:C16809
        label: Magnetic Resonance Imaging
    results: >-
      Contusion, subdural haematoma, or other structural injury; persistent
      barrier leakage on contrast-enhanced sequences.
    evidence:
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          significant risk factors for later seizures were brain contusion with
          subdural hematoma, skull fracture, loss of consciousness or amnesia for
          more than one day, and an age of 65 years or older
        explanation: >-
          Establishes that the imaging findings themselves carry the risk
          information, which is why imaging is a risk-stratification step here
          and not only a structural survey.
      - reference: PMID:32919030
        reference_title: >-
          Long-lasting blood-brain barrier dysfunction and neuroinflammation
          after traumatic brain injury.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          MRI indicated persistent Gd leakage in the impacted cortex and thalamus
          of variable severity in all rats with TBI which correlated with
          fluorescein extravasation.
        explanation: >-
          Demonstrates that contrast-enhanced MRI can detect the persistent
          barrier leakage modelled in the pathophysiology section. Rat data; the
          same study confirmed chronic barrier dysfunction in human PTE autopsy
          tissue.
clinical_trials:
  - name: NCT01463033
    description: >-
      A pilot study of levetiracetam given acutely after traumatic brain injury,
      designed to establish safety, tolerability, pharmacokinetics, and
      feasibility, with two-year follow-up for pilot data on post-traumatic
      epilepsy. It is the empirical expression of the hope that a newer agent
      with preclinical antiepileptogenic activity might succeed where phenytoin
      failed.
    target_phenotypes:
      - preferred_term: Focal-onset seizure
        term:
          id: HP:0007359
          label: Focal-onset seizure
    evidence:
      - reference: clinicaltrials:NCT01463033
        reference_title: "Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy"
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Past attempts at preventing epilepsy by treatment with older
          antiepileptic drugs have been unsuccessful.
        explanation: >-
          The trial's own stated premise, which is this entry's prophylaxis
          paradox restated as a rationale for further study.
      - reference: clinicaltrials:NCT01463033
        reference_title: "Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy"
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Levetiracetam is a novel AED with potent antiepileptogenic properties
          in animal models of epilepsy.
        explanation: >-
          Records the preclinical rationale. Marked PARTIAL because
          antiepileptogenic activity in animal models is precisely the claim that
          this entry's human-model mismatch discussion treats as unestablished
          for humans.
  - name: NCT01048138
    status: COMPLETED
    description: >-
      A placebo-controlled randomized double-blind trial of biperiden, a
      muscarinic antagonist, as a disease-modifying agent after traumatic brain
      injury. It targets a mechanism rather than seizure threshold, which is the
      strategy this entry's prophylaxis discussion argues is required, and it is
      therefore the closest thing to a direct test of that argument.

      It completed, and it was negative. Analysis showed no evidence of benefit
      for either the incidence of post-traumatic epilepsy or mortality.

      The paper also reports more late post-traumatic seizures in the biperiden
      arm. The figure is a count-regression coefficient on the log scale, a
      difference in the logs of expected counts of 2.03 with a 95 percent
      confidence interval of 0.912 to 3.1597; the null for such a coefficient is
      zero, not one, so the interval excludes it and the reported p below 0.001
      is consistent. The estimate also survives adjustment for the on-scene
      Glasgow Coma Scale score, falling only to 1.857.

      The reason not to read that as drug harm is allocation imbalance, and the
      authors say so themselves: the biperiden arm tended toward more severe
      injuries by on-scene GCS and had more frequent bilateral brain lesions,
      both established risk factors for post-traumatic epilepsy. Their own
      conclusion names the unbalanced distribution of those variables as the
      reason larger studies are needed. The trial was additionally halted early
      for the COVID-19 pandemic and under-enrolled against its planned 132
      participants. Taken together it is a mechanism-targeted intervention,
      tested as the prophylaxis discussion prescribes, that failed to show
      benefit in an underpowered and imbalanced sample.
    target_phenotypes:
      - preferred_term: Focal-onset seizure
        term:
          id: HP:0007359
          label: Focal-onset seizure
    evidence:
      - reference: clinicaltrials:NCT01048138
        reference_title: "Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study"
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          There is no AED or medication that has been demonstrated to affect the
          development of post-traumatic epilepsy.
        explanation: >-
          States the absence of any established antiepileptogenic agent, which is
          the gap this entry's discussions are built around, from a trial
          registration rather than a review.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: REFUTE
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Data analysis indicated lack of evidence of biperiden for either, the
          incidence of post-traumatic epilepsy (2.6, 95%CI, 0.65-10.57; p =
          0.170) or the mortality rate (1.57, 95%CI, 0.73-3.38; p = 0.248).
        explanation: >-
          The published negative result. Recorded as REFUTE so the entry states
          plainly that the mechanism-targeted strategy has been tried in humans
          and did not work, rather than presenting the trial as a live prospect.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: REFUTE
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The frequency of late post-traumatic seizures was higher for biperiden
          group (2.03, 95%CI = 0.912-3.1597; p <0.001).
        explanation: >-
          A statistically significant excess of late seizures in the biperiden
          arm. The 2.03 is a difference in the logs of expected counts, so the
          relevant null is zero rather than one and the interval excludes it; the
          estimate holds at 1.857 after adjustment for the on-scene Glasgow Coma
          Scale score. It is recorded as a real finding but not as demonstrated
          drug harm, because the arms were imbalanced on injury severity in the
          direction that would produce exactly this result.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The trial began in January 2018 and was halted by researchers on March
          2020 (and terminated in December 2022) in the face of the global
          COVID-19 pandemic.
        explanation: >-
          The first interpretive caveat: the trial stopped early and
          under-enrolled against its planned 132 participants, so the negative
          primary result is underpowered and should not be read as a definitive
          refutation of anticholinergic antiepileptogenesis.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          patients treated with biperiden tended to show more severe injuries as
          demonstrated by lower score at GCSoS than patients treated with
          placebo. Also, bilateral brain lesions were more frequent in the
          biperiden group. Both characteristics, severe and bilateral lesions,
          were already described as risk factors for PTE
        explanation: >-
          The second and more consequential caveat, and the reason the excess of
          late seizures should not be read as drug harm. The arm that had more
          seizures was also the arm with more severe and more often bilateral
          injury, and both are established risk factors for post-traumatic
          epilepsy, so the imbalance runs in exactly the direction needed to
          produce this result without any drug effect.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The combined effect of variables known to have an impact on the
          likelihood of developing late post-traumatic seizures and its
          unbalanced frequency in the different groups is an aspect to be
          considered and underpins the need for larger studies.
        explanation: >-
          The authors' own reading of that imbalance, and their conclusion that
          it is why larger studies are needed. Carried so the entry's caveat is
          the one the source actually gives rather than an inference of its own.
differential_diagnoses:
  - name: Early Provoked Post-Traumatic Seizures
    description: >-
      Acute symptomatic seizures within seven days of injury. These are not
      epilepsy and do not by themselves establish the diagnosis, but they are
      routinely conflated with it, including in older literature. Distinguishing
      them matters because only these respond to prophylaxis.
    distinguishing_features:
      - Onset within the first seven days after the injury.
      - Provoked by the acute injury rather than by an established epileptic network.
      - Suppressible by short-term antiseizure prophylaxis.
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Short-term antiseizure prophylaxis reduces early provoked seizures, but
          no interventions prevent late unprovoked seizures or PTE.
        explanation: >-
          States the pharmacological dissociation that is the practical basis for
          separating these two entities.
  - name: Psychogenic Non-Epileptic Seizures
    description: >-
      Common after traumatic brain injury and frequently comorbid with genuine
      post-traumatic epilepsy, which makes the distinction a recurring clinical
      problem rather than an academic one. Video-EEG is required to separate them.
    distinguishing_features:
      - No ictal EEG correlate during a captured typical event.
      - Semiology that does not conform to a recognized seizure pattern.
  - name: Chronic Traumatic Encephalopathy
    description: >-
      Also a delayed consequence of head trauma, but a neurodegenerative
      tauopathy associated with repetitive impacts, defined neuropathologically
      and presenting with cognitive and behavioural decline rather than with
      recurrent seizures as the cardinal feature. dismech carries a separate
      entry.
    distinguishing_features:
      - Repetitive rather than single severe head impacts.
      - Progressive cognitive and behavioural decline as the leading feature.
      - Neuropathological diagnosis based on perivascular tau pathology.
discussions:
  - discussion_id: pte_prophylaxis_does_not_prevent_epileptogenesis
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Antiseizure prophylaxis after head injury abolishes early seizures but does
      nothing to the late epilepsy. Why does suppressing seizure expression during
      the acute phase leave epileptogenesis untouched, and what does that tell us
      about which node the drug is actually acting on?
    attaches_to:
      - pathophysiology#Epileptogenesis During the Latent Period
      - pathophysiology#Traumatic Brain Injury
    rationale: >-
      This is the central negative result of the field and it has a clean
      mechanistic reading that the entry encodes structurally. The pivotal
      randomized trial showed phenytoin cutting first-week seizures from 14.2 to
      3.6 percent, then no benefit at all from day eight onward, with late rates
      numerically higher on drug at both one and two years. That dissociation is
      why this entry attaches prophylaxis to the injury node with MODULATES
      rather than to the epileptogenesis node: the drug raises seizure threshold
      in an acutely injured brain, and seizure threshold is simply not the same
      variable as the network reorganization that produces epilepsy. Three
      implications follow. First, an anticonvulsant screen will never find an
      antiepileptogenic drug, because the two are different endpoints. Second,
      the finding argues against early seizures being a major causal driver of
      epileptogenesis, since abolishing them changes nothing downstream, though it
      does not exclude a small effect. Third, any genuine prevention trial has to
      target one of the mechanism nodes upstream, the inflammasome, barrier,
      glial, or plasticity arms, rather than seizure expression. The gap is that
      no such trial has succeeded, so the causal sufficiency of any single
      upstream node remains unestablished in humans.
    proposed_experiments:
      - experiment_id: exp_pte_mechanism_targeted_prevention_trial
        name: Mechanism-targeted post-traumatic epilepsy prevention trial
        description: >-
          A randomized prevention trial in high-risk traumatic brain injury
          patients using an agent directed at an upstream mechanism node rather
          than at seizure threshold, such as an IL-1 receptor antagonist or an
          mTOR inhibitor, with late unprovoked seizures over at least two years as
          the primary endpoint.
        decision_criterion: >-
          A reduction in late unprovoked seizures without a corresponding
          anticonvulsant effect would establish that the targeted node is causally
          necessary for epileptogenesis in humans and would separate
          antiepileptogenesis from anticonvulsant action as endpoints.
      - experiment_id: exp_pte_early_seizure_causal_contribution
        name: Test whether early seizures causally contribute to later epilepsy
        description: >-
          Pooled or individual-participant analysis of prophylaxis trials asking
          whether patients whose early seizures were successfully suppressed
          differ in late epilepsy risk from those who had breakthrough early
          seizures, adjusted for injury severity.
        decision_criterion: >-
          Equivalent late risk regardless of early-seizure suppression would
          confirm early seizures as a severity marker rather than a causal step
          and would justify removing them from causal models entirely.
    evidence:
      - reference: PMID:2115976
        reference_title: >-
          A randomized, double-blind study of phenytoin for the prevention of
          post-traumatic seizures.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Between day 8 and the end of year 1, 21.5 percent of the phenytoin
          group and 15.7 percent of the placebo group had seizures; at the end of
          year 2, the rates were 27.5 percent and 21.1 percent, respectively
        explanation: >-
          The primary negative finding this discussion is built on: no late
          benefit despite a large early effect in the same trial and population.
      - reference: PMID:2115976
        reference_title: >-
          A randomized, double-blind study of phenytoin for the prevention of
          post-traumatic seizures.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          This lack of a late effect could not be attributed to differential
          mortality, low phenytoin levels, or treatment of some early
        explanation: >-
          The trialists explicitly excluded the obvious artefactual explanations,
          which is what makes the negative result mechanistically informative
          rather than merely inconclusive.
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Short-term antiseizure prophylaxis reduces early provoked seizures, but
          no interventions prevent late unprovoked seizures or PTE.
        explanation: >-
          Confirms that the dissociation still stands in current practice and is
          not an artefact of one older trial.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: REFUTE
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Data analysis indicated lack of evidence of biperiden for either, the
          incidence of post-traumatic epilepsy (2.6, 95%CI, 0.65-10.57; p =
          0.170) or the mortality rate (1.57, 95%CI, 0.73-3.38; p = 0.248).
        explanation: >-
          The one published human test of the strategy this discussion proposes,
          a mechanism-targeted agent rather than an anticonvulsant, and it was
          negative. Recorded as REFUTE against the proposed resolution rather
          than hidden, though the trial stopped early and was underpowered, so it
          weakens rather than closes the argument.
      - reference: PMID:39175759
        reference_title: >-
          Initial clinical evidence on biperiden as antiepileptogenic after
          traumatic brain injury-a randomized clinical trial.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The frequency of late post-traumatic seizures was higher for biperiden
          group (2.03, 95%CI = 0.912-3.1597; p <0.001).
        explanation: >-
          Retained as a hypothesis to test, not as an observed pattern. Both
          trials produced estimates in the direction of more late seizures rather
          than fewer, but the phenytoin difference (27.5 versus 21.1 percent) was
          non-significant, and the biperiden excess, though statistically robust,
          arose in a trial whose treated arm was more severely and more often
          bilaterally injured. So one arm of the apparent cross-trial signal is
          underpowered and the other is confounded. It is worth recording only
          because the direction is the opposite of what either drug was given
          for, and a prospective test would be cheap to specify.
  - discussion_id: pte_no_validated_epileptogenesis_biomarker
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Post-traumatic epilepsy has the one thing every other epilepsy lacks, a
      dated initiating insult and an identifiable at-risk population, yet no
      prevention trial has succeeded. Is the missing ingredient a biomarker that
      identifies who is actually undergoing epileptogenesis?
    attaches_to:
      - pathophysiology#Epileptogenesis During the Latent Period
    rationale: >-
      Most patients with traumatic brain injury never develop epilepsy, so a
      prevention trial enrolling on injury severity alone dilutes any true effect
      into a population that was mostly never going to convert. Even after severe
      injury the standardized incidence ratio of 17 corresponds to a minority of
      patients converting. That forces either impractically large trials or long
      follow-up, and it means a genuinely effective agent could fail for
      statistical rather than biological reasons. Candidate enrichment markers
      exist across several modalities, including neuroimaging, EEG signatures,
      circulating cytokines, and microRNAs, but none is validated for the
      purpose. There is a second, subtler problem: the latent period is defined
      by the absence of seizures, so it is currently a diagnosis of exclusion made
      retrospectively once seizures appear. Without a positive marker there is no
      way to confirm that a treated patient was ever undergoing epileptogenesis,
      which makes a negative trial uninterpretable.
    proposed_experiments:
      - experiment_id: exp_pte_prospective_biomarker_validation
        name: Prospective multimodal biomarker validation cohort
        description: >-
          A prospective cohort of patients with moderate to severe traumatic brain
          injury with serial imaging, EEG, and blood sampling from the acute phase
          onward, followed for at least five years, testing whether any single or
          combined marker predicts conversion to late unprovoked seizures with
          enough discrimination to enrich a trial.
        decision_criterion: >-
          A marker or panel achieving sufficient positive predictive value to
          reduce required trial size by a meaningful factor would unblock
          prevention trials; failure of all candidates would indicate that
          enrichment must come from injury phenotyping instead.
      - experiment_id: exp_pte_latent_period_positive_marker
        name: Search for a positive marker of ongoing epileptogenesis
        description: >-
          Test whether any candidate marker changes dynamically during the latent
          period in converters but not non-converters, so that epileptogenesis can
          be identified while it is happening rather than inferred after the first
          seizure.
        decision_criterion: >-
          A marker that tracks the process rather than the eventual outcome would
          make the latent period a positively defined state and would allow
          treatment response to be measured before seizures occur.
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Predictive biomarkers (neuroimaging, EEG, cytokines, microRNAs) are
          essential for risk stratification in prophylactic trials.
        explanation: >-
          States the biomarker requirement and enumerates the candidate
          modalities, none of which is yet validated.
      - reference: PMID:9414327
        reference_title: >-
          A population-based study of seizures after traumatic brain injuries.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The standardized incidence ratio was 1.5 (95 percent confidence
          interval, 1.0 to 2.2) after mild injuries but with no increase over the
          expected number after five years, 2.9 (95 percent confidence interval,
          1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence
          interval, 12.3 to 23.6) after severe injuries.
        explanation: >-
          Quantifies why enrichment is necessary: even the highest-risk severity
          stratum converts at a rate that leaves most enrolled patients unable to
          contribute an event.
  - discussion_id: pte_preclinical_to_human_translation_failure
    kind: HUMAN_MODEL_MISMATCH
    status: OPEN
    prompt: >-
      Several agents reduce seizure burden in rodent models of post-traumatic
      epilepsy, yet none has prevented epilepsy in humans. Is that a failure of
      the compounds, of trial design, or of the models themselves?
    attaches_to:
      - pathophysiology#Neuroinflammation and Inflammasome Activation
      - pathophysiology#Epileptogenesis During the Latent Period
    rationale: >-
      The candidate antiepileptogenic agents most often named, IL-1 receptor
      antagonists, mTOR inhibitors, and glutamate modulators such as ceftriaxone,
      rest on preclinical data showing reduced seizure burden. The mismatch is
      recorded as a human-model problem rather than a knowledge gap because the
      evidence exists and is positive; what is unestablished is whether it
      transfers. Several structural differences are candidates. Rodent models
      compress a latent period that in humans can run for years into weeks, so a
      treatment window that looks adequate in a mouse may be wrong by an order of
      magnitude in a patient. Model injuries are stereotyped and delivered to
      young healthy animals, whereas human traumatic brain injury is
      heterogeneous in mechanism, location, and severity, and its highest-risk
      group includes patients over 65. Most importantly, preclinical endpoints are
      usually seizure burden or frequency, which is an anticonvulsant readout, not
      the binary conversion-to-epilepsy endpoint a human prevention trial must
      use. Given that the field already knows anticonvulsant action dissociates
      from antiepileptogenesis in this disorder, a preclinical seizure-burden
      reduction may be measuring precisely the wrong thing.
    proposed_experiments:
      - experiment_id: exp_pte_model_endpoint_alignment
        name: Realign preclinical endpoints to conversion rather than burden
        description: >-
          Evaluate candidate antiepileptogenic agents in animal models using
          proportion of animals developing spontaneous recurrent seizures as the
          primary endpoint, with treatment withdrawn well before assessment so
          that residual anticonvulsant action cannot mask the result.
        decision_criterion: >-
          Agents that reduce conversion rate after washout are genuinely
          antiepileptogenic candidates; agents that only reduce seizure burden on
          drug are anticonvulsants and should not enter prevention trials.
      - experiment_id: exp_pte_model_human_injury_correspondence
        name: Correspondence of model injury to high-risk human injury phenotypes
        description: >-
          Systematic comparison of the histopathological and imaging features of
          standard rodent post-traumatic epilepsy models against the human injury
          features that actually carry risk, namely contusion with subdural
          haematoma, penetrating injury, and older age.
        decision_criterion: >-
          Poor correspondence, particularly on the lesion types that dominate
          human risk, would indicate the models are testing a different disease
          and would justify developing models built around those features.
    evidence:
      - reference: PMID:41187576
        reference_title: >-
          The path to post-traumatic epilepsy: A review of emerging biomarkers
          and therapeutic targets.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Promising repurposed agents include IL-1 receptor antagonists
          (anakinra), mTOR inhibitors (rapamycin), and glutamate modulators
          (ceftriaxone), with preclinical data showing reduced seizure burden.
        explanation: >-
          Names the candidate agents and, critically, identifies the supporting
          evidence as preclinical and the endpoint as seizure burden, which is the
          mismatch this discussion records.
      - reference: PMID:35302046
        reference_title: >-
          Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
          Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Differences in injury patterns, latency period, and biomarkers are
          outlined in the context of animal model validation
        explanation: >-
          Identifies injury pattern and latency differences as explicit model
          validation concerns, which are two of the structural mismatches named in
          the rationale.
      - reference: PMID:35302046
        reference_title: >-
          Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular
          Mechanisms, Biomarkers, and Novel Therapeutic Interventions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          There is currently no approved treatment that can prevent onset of
          spontaneous seizures associated with brain injury
        explanation: >-
          Confirms the human-side half of the mismatch, that no preventive
          treatment has translated despite the preclinical signal.

📚

References & Deep Research

References

2

PMID:35302046

Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

No top-level findings curated for this source.

PMID:41187576

The path to post-traumatic epilepsy: A review of emerging biomarkers and therapeutic targets.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Post-Traumatic Epilepsy (PTE) — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-5[1m] 22 citations 2026-08-05T00:28:07.519432

Post-Traumatic Epilepsy (PTE) — Comprehensive Research Report

Prepared: 2026-08-05 · Target entity: MONDO:0043264 post-traumatic epilepsy · Category: Complex / acquired (non-Mendelian)

A note on how to read this. PTE is not a genetic disease that happens to have an environmental trigger — it's the reverse. It's an acquired epilepsy where a single dated insult (the head injury) starts a clock, and over weeks to years the brain quietly rewires itself into something that seizes. That makes it unusually valuable: unlike almost every other epilepsy, you know exactly when the wound was made, so you can watch the scar form. That's why the field treats it as the model system for human epileptogenesis.

Verification status. Ontology IDs below marked ✅ were checked against local OAK adapters during this session (sqlite:obo:{hp,go,cl,uberon,chebi,ncit,mondo}). Citations marked ✅ had their abstracts fetched and quoted verbatim. Citations marked ⚠️ come from secondary/search-summary sources and must be re-fetched with just fetch-reference PMID:… and snippet-verified before being committed as dismech evidence.

1. Disease Information

Overview

Post-traumatic epilepsy is a recurrent, unprovoked seizure disorder that develops as a consequence of traumatic brain injury (TBI). The defining feature is latency: the seizures that matter are the late ones (>7 days post-injury), separated from the trauma by a silent interval during which the injured tissue is remodeling itself into an epileptogenic network.

The conventional temporal taxonomy — and it matters, because the three categories have different mechanisms, different predictive value, and different treatment implications:

Category	Timing	Nature
Immediate post-traumatic seizures	<24 h	Largely acute symptomatic / concussive convulsions; often non-epileptic
Early post-traumatic seizures	≤7 days	Acute symptomatic (provoked); preventable by short-course ASMs; a risk marker for PTE, not PTE itself
Late post-traumatic seizures	>7 days	Unprovoked; constitute PTE

Per current ILAE criteria, epilepsy may be diagnosed after two unprovoked seizures or one unprovoked seizure with a ≥60% ten-year recurrence risk. Because the recurrence risk after a single late seizure following severe TBI is roughly 80% at 10 years, a single late post-traumatic seizure after severe TBI is sufficient to diagnose PTE ⚠️ (recurrence figure reported as "82% at 10 years… 62% within one year" — verify against the primary source).

Key identifiers

Resource	Identifier	Status
MONDO	MONDO:0043264 post-traumatic epilepsy	✅ verified via OAK
MeSH	D004834 (Epilepsy, Post-Traumatic)	✅ (MONDO xref)
UMLS	C0014557	✅ (MONDO xref)
SNOMED CT	75023009	✅ (MONDO xref)
MedGen	4991	✅ (MONDO xref)
OMIM	none — not a Mendelian entity	—
Orphanet	none — not a rare disease	—
ICD-10-CM	No dedicated code. Coded as epilepsy (`G40.-`, commonly `G40.209`) plus sequela of intracranial injury (`S06.-` with 7th character S, or `T90.5`)	⚠️ verify against current coding guidance
ICD-11	Epilepsy `8A6-` block; structural etiology qualifier; no unique PTE stem code	⚠️ verify

Synonyms (from MeSH D004834 via MONDO) ✅

post-traumatic epilepsy (exact); epilepsy, traumatic; traumatic epilepsy; post-traumatic seizure disorder; early post-traumatic seizures; late post-traumatic seizures; impact seizure; concussive convulsion(s).

Curation caution: MONDO's inherited MeSH synonym list lumps "early post-traumatic seizures" and "concussive convulsions" under this term. Mechanistically these are acute symptomatic seizures, not epilepsy. The MONDO definition itself flags this: "Concussive convulsions are nonepileptic phenomena that occur immediately after head injury" ✅ (MONDO:0043264 def). This is a genuine ontology-vs-biology mismatch worth recording as a discussions note in the dismech entry.

Information provenance

Both. Modern PTE epidemiology is dominated by individual-patient registry/EHR linkage (Norwegian Trauma Registry, Swedish national registers, Taiwan NHI, US Level 1 trauma centers, TRACK-TBI, EpiBioS4Rx). Mechanistic content is overwhelmingly model-organism derived (rodent lateral fluid percussion and controlled cortical impact). Aggregated disease-level resources (Orphanet, OMIM) contribute essentially nothing here.

2. Etiology

Primary causal factor

Traumatic brain injury. The mechanical insult is necessary; nothing else in this entry substitutes for it. Everything downstream is dose-response on injury severity and lesion type.

Risk factors — environmental / injury-related

The strongest predictors are all properties of the injury itself:

Injury severity — the dominant gradient. Annegers et al. ✅ (PMID:9414327, N Engl J Med 1998;338:20-4) followed 4,541 TBI patients in Olmsted County, MN (1935–1984): "The overall standardized incidence ratio was 3.1", rising to "17.0 (95 percent confidence interval, 12.3 to 23.6)" after severe injuries, versus 2.9 (moderate) and 1.5 (mild, "with no increase over the expected number after five years").
Penetrating injury — the highest-risk category of all (see §9).
Intracranial hemorrhage / subdural hematoma / cortical contusion — Annegers ✅ named "brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia for more than one day, and an age of 65 years or older" as significant risk factors. Kazis et al. ⚠️ (PMID:38398011, Biomedicines 2024;12(2):410) report intracranial hemorrhage CIR 1.60.
Early post-traumatic seizures — the single strongest clinical marker. Kazis et al. ⚠️ report "occurrence of early seizures was significantly associated with an increased risk of PTE" (CIR 7.28).
Depressed skull fracture, coma >24 h, need for neurosurgical evacuation.
Age — bimodal risk. Elderly (≥65) per Annegers ✅; young children carry high risk in the abusive-head-trauma setting (§9).
Male sex — ~32% increased risk vs women ⚠️ (Kazis, PMID:38398011).
Alcohol misuse — history of alcohol abuse "more than doubling the likelihood of PTE" ⚠️ (Kazis, PMID:38398011).
Hospital-acquired infection during the acute admission — a striking, relatively new signal: adjusted RR 1.59 (95% CI 1.11–2.28; p=0.011) ⚠️ (registry-based cohort, PMC11296124). This is mechanistically coherent with the systemic-inflammation arm of epileptogenesis.

Risk factors — genetic

There is no causal gene. PTE genetics is entirely about modifier / susceptibility alleles, and the evidence base is weak. Cotter et al. ⚠️ (PMID:28242442, Seizure 2017) systematically reviewed candidate variants; Misra et al. ⚠️ (PMID:36912749, Eur J Neurol 2023) concluded that "current evidence on the association of genetic polymorphisms in epilepsy secondary to TBI or stroke is of low quality and lacks validation." Treat every allele below as SUSCEPTIBILITY with modest confidence. Details in §4.

Protective factors

Genetic protective factors: none established. (The APOE ε2/ε3 "protection" claim is just the inverse of a non-replicated ε4 risk signal — do not curate it as protective.)
Environmental/interventional protective factors:
Injury prevention is the only intervention with unambiguous benefit — helmets, restraints, fall prevention, body armor. Preventing the TBI prevents the epilepsy.
Short-course ASM prophylaxis (≤7 days) reduces early seizures but does not prevent PTE — a well-replicated null. Pease et al. ✅ note the field's premise that "Studies in preclinical models of PTE have identified tractable pathways and novel therapeutic strategies that can potentially prevent epilepsy, which remain to be validated in humans" — i.e., nothing is validated yet.
SSRIs have been examined as a modifier of post-TBI epilepsy risk in a population cohort ⚠️ (PLOS One 2019) — exploratory only.

Gene–environment interaction

The whole disease is a gene–environment interaction: a fixed environmental insult of measurable magnitude, filtered through host inflammatory and neurotransmitter genotype. The best-characterized example is IL1B rs1143634 ⚠️ (Diamond et al., PMID:26149793, Epilepsia 2015), where the CT genotype was associated with lower serum IL-1β, higher CSF/serum IL-1β ratio, and increased PTE risk — a genotype that changes how the brain compartmentalizes the injury's inflammatory response, rather than one that causes seizures on its own. That CSF/serum ratio detail is the mechanistically interesting part: the variant appears to shift where the cytokine ends up, not just how much there is.

3. Phenotypes

Core seizure phenotypes

Phenotype	HPO term	Verified	Characteristics
Recurrent unprovoked seizures	HP:0001250 Seizure	✅	Defining feature
Focal-onset seizures	HP:0007359 Focal-onset seizure	✅	Predominant type. MONDO def: "The majority of seizures have a focal onset that correlates clinically with the site of brain injury" ✅
Focal motor seizure	HP:0011153 Focal motor seizure	✅	Common with peri-rolandic contusion
Focal impaired-awareness seizure	HP:0011146 Dialeptic seizure	✅	Frequent with temporal/mesial involvement
Focal to bilateral tonic-clonic	HP:0002069 Bilateral tonic-clonic seizure	✅	Common presenting event
Status epilepticus	HP:0002133 Status epilepticus	✅	Occasional; higher acute mortality
Interictal EEG abnormality	HP:0002353 EEG abnormality	✅	Epileptiform discharges; HFOs (see §10)

Generalized-onset seizures (HP:0002197 ✅) and myoclonic seizures (HP:0032794 ✅) are uncommon and should prompt reconsideration of the diagnosis.

Structural / imaging phenotypes

Phenotype	HPO term	Verified
Intracranial hemorrhage (index injury)	HP:0002170	✅
Gliosis (perilesional)	HP:0002171	✅
Hippocampal atrophy	HP:0410170	✅
Cerebral cortical atrophy	HP:0002120	✅

Comorbid / neuropsychiatric phenotypes

Golub & Reddy ⚠️ (PMID:35302046, Pharmacol Rev 2022;74:387-438) frame this well: "A variety of comorbidities, including difficulty focusing, anxiety, learning and memory impairment, motor dysfunction, and sleep disturbances reduce the quality of life for many patients with PTE."

Phenotype	HPO term	Verified	Notes
Cognitive impairment	HP:0100543	✅	Additive on top of baseline TBI deficit
Memory impairment	HP:0002354	✅
Depression	HP:0000716	✅	Bidirectional with seizure burden
Anxiety	HP:0000739	✅
Irritability	HP:0000737	✅
Sleep disturbance	HP:0002360	✅
Psychosis	HP:0000709	✅	Less common
Headache	HP:0002315	✅	Frequently persistent post-traumatic headache

Onset, severity, progression, frequency

Age of onset: any; determined by age at injury, not by a developmental program.
Latency from injury to first late seizure: the signature parameter. Kazis et al. ⚠️ (PMID:38398011), n=2,862: "latency period… ranging from 8 days to 20 years. The median latency period was 24.0 months." Most cases declare within 2 years; a real tail extends decades (§8).
Severity: variable. Roughly one third become drug-resistant — Pease et al. ⚠️ describe "approximately one-third of patients with PTE fail to achieve seizure freedom despite treatment with multiple antiseizure medications."
Progression: episodic (seizures) on a background that is usually stable-to-slowly-progressive; not a neurodegenerative trajectory in the ALS sense, though repeated seizures worsen recovery. Pease et al. ✅: "The repeated seizures that characterize PTE impair neurological recovery and increase the risk of poor outcomes after TBI."
Frequency among affected individuals: see §9 for population-level incidence.

Quality of life

No PTE-specific validated instrument; QOLIE-31/QOLIE-89 (epilepsy-specific), SF-36, and EQ-5D are used, alongside GOS-E for TBI outcome. PTE independently predicts worse long-term functional outcome after severe TBI ⚠️ (Neurology 2023, doi:10.1212/WNL.0000000000207183). Driving restriction, employment loss, and ASM cognitive side effects are the dominant day-to-day burdens — the drugs meant to help can themselves blunt the cognition the injury already dented.

4. Genetic / Molecular Information

Causal genes: none. PTE is an acquired, non-Mendelian condition. Do not curate a genetic: block implying causation; use relationship_type: SUSCEPTIBILITY / MODIFIER throughout.

Candidate modifier / susceptibility loci

From Cotter et al. ⚠️ (PMID:28242442) and Misra et al. ⚠️ (PMID:36912749):

Gene	Variant	Reported effect	Confidence
IL1B (hgnc:5992 ⚠️ — verify)	rs1143634	CT genotype → lower serum IL-1β, higher CSF/serum ratio, ↑ PTE risk (p=0.005; "Those with IL-1β rs1143634 CT genotype developed PTE in 47.7% of cases (p = 0.008)" ⚠️)	Best-supported single signal (PMID:26149793)
ADORA1 (adenosine A1 receptor)	rs10920573, rs3766553	↑ PTE risk; rs10920573 among "most promising"	Moderate
GAD1 (glutamate decarboxylase 1)	rs3828275, rs3791878, rs769391	Altered GABA synthesis capacity → PTE risk	Weak–moderate
APOE	ε4 allele	"Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon4 allele" (PMID:12810485 ⚠️); but meta-analysis OR 1.8 (95% CI 0.6–5.6) — non-significant ⚠️	Inconsistent; curate as REFUTE/PARTIAL alongside the original claim
MTHFR	C677T	Reported association	Weak
UGT1A6 / CYP2C9	—	Associated with valproate levels and early post-traumatic seizures (PMC5574127 ⚠️) — pharmacokinetic, not epileptogenic	Pharmacogenomic, distinct claim
ADORA2A	rs2298383	Associated with epilepsy risk in Chinese pediatric general epilepsy, not PTE ⚠️	Do not curate as a PTE association — this is a scope error the search literature repeatedly makes

Variant classification: all of the above are common polymorphisms / susceptibility alleles, not ACMG-classifiable pathogenic variants. No ClinVar pathogenic entries exist for PTE as such. All germline; allele frequencies are common (gnomAD MAF typically >0.05) — check gnomAD per-variant before curating.

Functional consequence: regulatory/quantitative rather than loss-of-function — altered cytokine production (IL1B), altered adenosinergic tone (ADORA1), altered GABA synthesis (GAD1), altered lipid handling/repair (APOE).

Epigenetics

Not well characterized in human PTE. Preclinical work implicates chromatin-level regulation of inflammatory and glutamatergic genes and, most concretely, miRNA dysregulation — see §10 for the EpiBioS4Rx plasma miRNA data (miR-212-3p, miR-132-3p, miR-183-5p, miR-323-3p, miR-434-3p, miR-9a-3p, miR-124-3p) ✅ (PMID:39661396). A genuine knowledge gap worth a KNOWLEDGE_GAP discussion entry.

Chromosomal abnormalities

None. Not applicable.

5. Environmental Information

Primary environmental factor: mechanical trauma to the head — motor vehicle collisions, falls (dominant in the elderly), assaults, sports, blast and ballistic injury, abusive head trauma in infants.
Occupational/military exposure: combat penetrating head injury carries the highest documented PTE risk of any exposure (§9).
Lifestyle: alcohol misuse operates twice — as a cause of injury and as an independent risk amplifier for PTE ⚠️ (Kazis, PMID:38398011).
Infectious agents: not causal. But hospital-acquired infection during the acute admission is an emerging risk factor (aRR 1.59) ⚠️ (PMC11296124), plausibly acting through systemic inflammatory amplification of the neuroinflammatory cascade. Post-traumatic CNS infection (meningitis, abscess after penetrating injury or CSF leak) adds independent epileptogenic risk.

6. Mechanism / Pathophysiology

This is where the dismech entry earns its keep. The causal chain below is proposed as the pathophysiology graph; every node has a plausible biological_scale tag.

The causal chain (trigger → clinical manifestation)

Node 1 — Mechanical Brain Injury and Primary Tissue Disruption (TISSUE) Contusion, axonal shearing, vascular tearing, hemorrhage. This is the only genuinely upstream event. UBERON:0000955 brain ✅; UBERON:0000956 cerebral cortex ✅.

Node 2 — Blood–Brain Barrier Breakdown and Serum Protein Extravasation (TISSUE) The barrier fails and serum albumin floods the neuropil. This is the best-worked-out mechanistic arm in the entire field. UBERON:0000120 blood brain barrier ✅; CL:0000071 blood vessel endothelial cell ✅.

Node 3 — Astrocytic Albumin Uptake via TGF-β Receptor / ALK5 Signaling (MOLECULAR) Astrocytes take up extravasated albumin through TGF-β receptor signaling, which switches on a transcriptional program. Ivens et al. ⚠️ (PMID:17121744, Brain 2007) — "TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis." Weissberg et al. ⚠️ (PMID:25836421, Neurobiol Dis 2015): "Activation of the astrocytic ALK5/TGF-β-pathway induces excitatory, but not inhibitory, synaptogenesis that precedes the appearance of seizures." GO:0007179 transforming growth factor beta receptor signaling pathway ✅; CL:0000127 astrocyte ✅; GO:0048143 astrocyte activation ✅.

Node 4 — Neuroinflammatory Amplification (CELLULAR) Microglial activation, IL-1β/IL-1R1 signaling, NLRP3 inflammasome, HMGB1/TLR4, IL-6, TNF, MMP-9. This arm both sustains BBB leakage (a feed-forward loop — the leak feeds the inflammation that widens the leak) and directly lowers seizure threshold via IL-1β-mediated NMDA receptor phosphorylation. GO:0150076 neuroinflammatory response ✅; GO:0006954 inflammatory response ✅; GO:0001774 microglial cell activation ✅; CL:0000129 microglial cell ✅; CL:0000738 leukocyte ✅.

Node 5 — Iron Deposition and Oxidative/Ferroptotic Injury (MOLECULAR) Extravasated erythrocytes break down; hemoglobin → heme → free iron drives Fenton chemistry, lipid peroxidation, and ferroptosis in perilesional tissue. Direct cortical injection of hemoglobin or FeCl₃ produces chronic epileptic seizures in rats ⚠️ — the classic iron-induced epilepsy model. Ferroptosis inhibition (baicalein) reduces seizure score, number, and duration in FeCl₃-induced PTE ⚠️ (PMC6568039); iron chelation with deferoxamine suppresses epilepsy in the same paradigm ⚠️. GO:0097707 ferroptosis ✅; GO:0006979 response to oxidative stress ✅; CHEBI:29033 iron(2+) ✅; CHEBI:4356 desferrioxamine B ✅. (Note: GO:0055072 "iron ion homeostasis" is obsolete ✅ — do not use it.)

Node 6 — Loss of Inhibitory Interneurons and Chloride-Homeostasis Failure (CELLULAR) Selective vulnerability of hilar parvalbumin- and somatostatin-expressing GABAergic interneurons; downregulation of the K-Cl cotransporter KCC2 (SLC12A5) shifts the GABA_A reversal potential so that GABA becomes depolarizing rather than hyperpolarizing. The brake doesn't just wear out — it starts pushing. CL:0000617 GABAergic neuron ✅; CHEBI:16865 gamma-aminobutyric acid ✅. (No verified CL term for "parvalbumin-positive interneuron" was found in this session — use CL:0000617 with a more specific preferred_term.)

Node 7 — Excitatory Synaptic Reorganization and Aberrant Plasticity (CELLULAR) Mossy fiber sprouting in the dentate gyrus creating recurrent excitatory circuits; excitatory synaptogenesis driven by Node 3; mTORC1 pathway activation driving aberrant growth; impaired astrocytic glutamate clearance (EAAT2/GLT-1) raising extracellular glutamate. GO:0050808 synapse organization ✅; GO:0031929 TOR signaling ✅; GO:0035249 synaptic transmission, glutamatergic ✅; GO:0014048 regulation of glutamate secretion ✅; GO:0060291 long-term synaptic potentiation ✅; UBERON:0001885 dentate gyrus of hippocampal formation ✅.

Node 8 — Reactive Gliosis and Perilesional Scar (TISSUE) Astroglial scar with altered potassium buffering (Kir4.1 downregulation) and aquaporin-4 mislocalization. HP:0002171 Gliosis ✅; CL:0000125 glial cell ✅.

Node 9 — Hyperexcitable, Hypersynchronous Network (CELLULAR/TISSUE) The convergent endpoint. Pease et al. ✅ define it: "Epileptogenesis is the process whereby previously normal brain tissue becomes prone to recurrent abnormal electrical activity, ultimately resulting in seizures."

Node 10 — Recurrent Unprovoked Seizures (PTE) (ORGANISM) Clinical manifestation. Feeds back onto Nodes 4 and 6 — seizures beget seizures.

Module conformance opportunities (dismech-specific)

This entry is a strong conformer to the existing epilepsy_excitation_inhibition_imbalance module (key target: #Excitation-Inhibition Imbalance) — Nodes 6, 7, 9 map almost directly. Node 8 has partial affinity to fibrotic_response (glial scarring is the CNS analog, though not a true myofibroblast/ECM program — flag rather than force it). Node 5 is a candidate anchor if a ferroptosis/iron-injury module is ever created.

Upstream vs downstream summary

Upstream and irreversible: Nodes 1–2. The therapeutic window sits in Nodes 3–5 (the latent period), which is precisely why every antiepileptogenesis trial targets TGF-β, IL-1, mTOR, or iron. Nodes 6–9 are downstream consolidation; once they're set, you're treating epilepsy, not preventing it.

Metabolic, proteomic, transcriptomic

Metabolic: post-traumatic mitochondrial dysfunction, impaired glucose metabolism, altered adenosine tone (adenosine kinase upregulation is a proposed epileptogenic mechanism in acquired epilepsy generally ⚠️ — the PTE-specific evidence was not confirmed in this session).
Proteomic/fluid: IL-6, IL-8, IL-10, HMGB1, MMP-9 evaluated prospectively in TBI→PTE cohorts; results largely negative (see §10) ⚠️ (PMC12676904).
Transcriptomic: plasma miRNA signatures ✅ (PMID:39661396); brain-tissue single-cell data for human PTE are essentially absent — a clear KNOWLEDGE_GAP.

7. Anatomical Structures Affected

Organ: brain (UBERON:0000955 ✅). System: nervous system, exclusively (secondary systemic effects follow from seizures and ASM exposure, not from the disease process).

Regional predilection — TBI preferentially damages the polar regions where brain meets bone:

Structure	UBERON	Verified	Role
Cerebral cortex	UBERON:0000956	✅	Contusion sites; focal seizure onset zones
Neocortex	UBERON:0001950	✅	Perilesional epileptogenic cortex
Frontal lobe	UBERON:0016525	✅	Common contusion site (orbitofrontal)
Temporal lobe	UBERON:0001871	✅	Common contusion site; mesial temporal onset
Hippocampal formation	UBERON:0002421	✅	Sclerosis, mossy fiber sprouting
Ammon's horn	UBERON:0001954	✅	CA1/CA3 neuronal loss
Dentate gyrus	UBERON:0001885	✅	Hilar interneuron loss; granule cell reorganization
Entorhinal cortex	UBERON:0002728	✅	Layer III vulnerability
Blood–brain barrier	UBERON:0000120	✅	Site of the initiating leak

Cell populations: CL:0000540 neuron ✅, CL:0000598 pyramidal neuron ✅, CL:0002608 hippocampal neuron ✅, CL:0000617 GABAergic neuron ✅, CL:0000127 astrocyte ✅, CL:0000129 microglial cell ✅, CL:0000125 glial cell ✅, CL:0000071 blood vessel endothelial cell ✅, CL:0000128 oligodendrocyte ✅.

Subcellular: mitochondria (oxidative injury), plasma membrane (KCC2, EAAT2, Kir4.1, aquaporin-4 mislocalization), synapse (excitatory synaptogenesis), lysosome (astrocytic albumin trafficking). Bind GO Cellular Component terms at curation time — none were verified in this session.

Lateralization: typically unilateral/asymmetric, tracking the lesion; bilateral in diffuse or blast injury and in abusive head trauma. Notably, "A left parietal lobe lesion and the presence of hemosiderin staining were linked to the development of PTE" ⚠️ — a lateralization signal that has not been consistently replicated.

8. Temporal Development

Onset pattern: insidious, following a defined latent period. This is a secondary/acquired onset — age of onset = age at injury + latency.

Latency distribution ⚠️ (Kazis, PMID:38398011, n=2,862): median 24.0 months; range 8 days to 20 years. Most cases declare within the first 2 years; the risk curve flattens but never reaches zero.

The very long tail is real and clinically important. Raymont et al. ⚠️ (PMID:20644150, Neurology 2010), Vietnam Head Injury Study phase 3 at 30–35 years post-injury: seizure prevalence 43.7% (87/199), and "11 of 87 (12.6%) reported very late onset of PTE after phase 2 (more than 14 years after injury)." PTE can first appear 35 years after a combat head injury.

Severity-dependent duration of excess risk: Annegers ✅ found mild injuries carried elevated risk "with no increase over the expected number after five years" — i.e., mild TBI risk is transient, severe TBI risk is lifelong.

Disease stages: 1. Acute/insult phase (0–7 days) — primary + secondary injury, early symptomatic seizures. 2. Latent phase / epileptogenesis (days → months–years) — clinically silent, biologically busy. The therapeutic window. 3. Chronic phase — established PTE with recurrent unprovoked seizures. 4. Refractory phase (~⅓ of patients) — drug resistance, surgical evaluation.

Course: chronic, lifelong once established; seizures episodic. Remission: spontaneous remission occurs but is less common than in idiopathic generalized epilepsies; treatment-induced seizure freedom is achieved in roughly two-thirds.

Critical period: days-to-weeks after injury. Every antiepileptogenic strategy in §12 is an attempt to intervene here.

9. Inheritance and Population

Epidemiology

Fraction of all epilepsy: - Pease et al. ✅: "Post-traumatic epilepsy (PTE) accounts for 5% of all epilepsies." - Kazis et al. ⚠️ (PMID:38398011): "Previous TBI accounts for approximately 5% of new cases and 20% of prevalent cases." - Commonly cited as 10–20% of symptomatic (structural) epilepsies ⚠️.

Cumulative incidence after TBI:

Cohort	Finding	Source
Olmsted County, US (1935–84)	SIR 3.1 overall; 1.5 mild / 2.9 moderate / 17.0 (95% CI 12.3–23.6) severe	✅ PMID:9414327
Norway, nationwide (2015–20), n=8,660 vs 84,024 controls	Cumulative epilepsy incidence 3.1% at 2 yr, 4.0% at 5 yr (controls 0.2% / 0.5%); severe TBI "11.8% [95% CI 9.7-14.4%] after 2 years and 13.2% [10.8-16.0%]" at 5 yr; 7.7× risk vs trauma-free controls over 5 yr	✅ PMID:38903174
Sweden, nationwide register	10-year risk 4.0% (95% CI 3.8–4.2) after any TBI vs 0.9% in controls	⚠️ Karlander et al., JNNP 2021;92:617-621 (PMID not verified)
Sweden, 10-yr by lesion type	Focal cerebral injury 12.9%; diffuse 8.1%; extracerebral 7.3%; skull fracture 2.8%; mild TBI 2.6%	⚠️ via PMID:38398011
Vietnam Head Injury Study (penetrating)	PTE prevalence 43.7–53%	⚠️ PMID:20644150, PMID:3929158
Severe non-penetrating TBI, Iran (n=803)	10.2% late post-traumatic seizures	⚠️
Pediatric abusive head trauma	~30% develop PTE within 2–5 yr; 36% by age 5 post-injury	⚠️

Curation note for the prevalence: block: use measure_type: PERIOD_PREVALENCE or ANNUAL_INCIDENCE as appropriate and record the base population (TBI survivors vs general population) in population: — these numbers are conditional on injury and are meaningless without it. For the general population, PTE prevalence should be derived as ~5% of epilepsy prevalence, giving roughly 30–40 per 100,000 (prevalence_class: BAND_1_5_PER_10000) — but this is a derivation, so mark it in notes: rather than dressing it up as a sourced figure.

Sex ratio: male predominance, driven both by TBI incidence (men sustain more severe TBI) and by a possible ~32% independent risk elevation ⚠️.

Age distribution: bimodal in risk — young children (especially abusive head trauma, reported risks "as high as 60%" ⚠️) and adults ≥65 (Annegers ✅). Peak absolute case numbers follow the young-adult male TBI peak.

Geographic distribution: follows TBI epidemiology — road-traffic injury burden in LMICs, falls in aging high-income populations, conflict zones for penetrating injury. No genetic founder effects; not applicable.

Inheritance

Not heritable. Inheritance pattern: multifactorial / not applicable. Do not populate inheritance: with an HPO mode-of-inheritance term. No penetrance, expressivity, anticipation, mosaicism, founder effect, consanguinity, or carrier frequency parameters apply.

10. Diagnostics

Clinical criteria — the actual diagnostic basis

PTE is a clinical diagnosis: a history of TBI plus ≥1 late (>7 day) unprovoked seizure meeting ILAE epilepsy criteria. There is no confirmatory test.

Differential diagnosis — and this is where most diagnostic error lives: - Psychogenic non-epileptic seizures (PNES) — markedly over-represented after TBI; requires video-EEG to distinguish. The single most important differential. - Acute symptomatic (provoked) seizures — metabolic derangement, drug/alcohol withdrawal, sepsis, hyponatremia. Provoked ≠ epilepsy. - Concussive convulsions — immediate, non-epileptic (explicitly noted in the MONDO definition ✅). - Syncope with convulsive features; post-traumatic movement disorders; sleep disorders. - Pre-existing epilepsy that predated the injury — or caused it (a seizure-induced fall producing the TBI).

Electrophysiology

Routine and prolonged EEG / continuous EEG (cEEG) — the diagnostic workhorse. Detects interictal epileptiform discharges and non-convulsive seizures.
High-frequency oscillations (HFOs) — ripples 80–250 Hz and fast ripples 250–500 Hz ⚠️ (PMID:38398011) are the leading electrophysiological biomarker candidate. "fast ripples representing pathological synchronization of cellular assemblies related to seizure onset zones" ⚠️.
Quantitative EEG — early (days 2–5) increased delta spectral power discriminates PTE risk after severe TBI ⚠️; preclinical accuracies near 95%/AUC ~0.98 have been reported ⚠️ and should be treated with appropriate skepticism given model-to-human gaps.

Imaging

CT (acute) — hemorrhage, contusion, fracture; establishes the injury substrate.
MRI with SWI/GRE — hemosiderin and microbleed detection. "Microbleeds of diffuse vascular injury and resulting iron residues… are robustly detected by susceptibility weighted imaging" ⚠️.
T1-weighted magnetization transfer MRI — "gliosis surrounding hemosiderin deposits… precede PTE" ⚠️.
DTI — decreased fractional anisotropy, increased mean diffusivity ⚠️ (PMID:38398011).
Dynamic contrast-enhanced MRI — BBB permeability quantification; mechanistically the most direct imaging readout of Node 2.
PET/SPECT, MEG — for surgical localization in refractory cases.

Fluid biomarkers

Honest summary: no validated fluid biomarker exists. A prospective international study of IL-6, IL-8, IL-10, HMGB1 and MMP-9 (blood at days 2 and 4, 24-month follow-up) concluded these "may not serve as sensitive biomarkers of PTE" — though "a faster decline in IL-6 levels in the non-PTE groups suggests a more rapid resolution of inflammation among patients who do not develop PTE" ⚠️ (PMC12676904). GFAP and S100B are validated for TBI severity/CT-positivity (GFAP AUC 0.85 vs S100B 0.67 in TRACK-TBI ⚠️, PMID:32854584) but not for PTE prediction.

The most rigorous prospective biomarker data are preclinical: Heiskanen et al. ✅ (PMID:39661396, Epilepsia 2025, EpiBioS4Rx Project 1, n=245 rats across Finland/Australia/USA): "None of the seven miRNAs differentiated TBI rats that did and did not develop epilepsy (p > .05)… However, miR-212-3p differentiated rats that developed epilepsy with seizure clusters… with an area under the curve (AUC) of .81." Conclusion: "miR-212-3p alone or in combination with miR-132-3p shows promise as a translational prognostic biomarker for the development of severe PTE with seizure clusters."

Curation note: this is a textbook HUMAN_MODEL_MISMATCH candidate — a rigorously harmonized multi-site rodent biomarker result whose human translation is entirely unestablished. Also note the EpiBioS4Rx harmonization methods paper ⚠️ (PMID:38056191) as the "first demonstration of the feasibility of protocol harmonization for performing powered preclinical multi-center trials."

Genetic testing

Not indicated. No diagnostic genetic test. WGS/WES/panels/CMA/karyotype/FISH/mtDNA/repeat-expansion testing all: not applicable. Genotyping of IL1B/ADORA1/APOE is research-only. The only defensible clinical genetic testing scenario is when the "post-traumatic" attribution is doubted and a genetic epilepsy is in the differential.

Screening

No population screening. Risk stratification of TBI survivors (severity, lesion type, early seizures, cEEG findings) is the practical analog, and is the enrolment strategy for antiepileptogenesis trials rather than a clinical service.

11. Outcome / Prognosis

Mortality. PTE substantially raises death risk above TBI alone: - Taiwan population-based cohort ⚠️: mortality IR 71.8 vs 27.6 per 1,000 person-years (PTE vs TBI alone); aHR 2.31 (95% CI 1.96–2.73). - Late post-traumatic seizures ⚠️ (PMID:19508123): 27% died at 8–15 years post-injury vs 10% without LPTS, and "individuals with LPTS died at a younger age (54.1 versus 67.7 years)" — over a decade of life lost. - Acquired epilepsy generally carries a median SMR ~2.3 ⚠️. - Excess mortality becomes evident roughly 1 year after injury ⚠️ (PMID:35852600, J Neurol 2022) — i.e., it is not just the acute injury killing people. - SUDEP risk applies as in other focal epilepsies (PTE-specific rates not well established — a knowledge gap).

Morbidity and function. PTE independently predicts worse long-term functional outcome after severe TBI ⚠️ (Neurology 2023). Pease et al. ✅: "The repeated seizures that characterize PTE impair neurological recovery and increase the risk of poor outcomes after TBI."

Treatment response. ~⅔ achieve seizure freedom on ASMs; ~⅓ are pharmacoresistant ⚠️. Golub & Reddy ⚠️ (PMID:35302046): "There is currently no approved treatment that can prevent onset of spontaneous seizures associated with brain injury, and many cases of PTE are refractory to antiseizure medications."

Prognostic factors: injury severity; penetrating vs closed; presence and volume of intracranial hemorrhage; early post-traumatic seizures; age; number of ASMs failed (the standard drug-resistance predictor); recurrence after a first late seizure (~80% at 10 years ⚠️).

Prognostic biomarkers: none validated. Candidates: HFOs, early delta power, DTI/SWI features, plasma miR-212-3p/miR-132-3p ✅ (rodent only).

12. Treatment

The central therapeutic fact

Nothing prevents PTE. Prophylactic ASMs reduce early seizures and do not touch late seizures or epileptogenesis. Pease et al. ⚠️: "Multiple randomized controlled trials have shown that short-term antiseizure prophylaxis does not prevent the development of PTE." Every treatment below is symptomatic.

Acute prophylaxis (early seizure prevention — NOT antiepileptogenesis)

Neurocritical Care Society 2024 guideline ✅ (Frontera JA et al., PMID:38316735, Neurocrit Care 2024) — the current authoritative statement, and refreshingly candid about how thin the evidence is:

"Based on GRADE criteria, we suggest that ASM or no ASM may be used in patients hospitalized with moderate-severe TBI (weak recommendation, low quality of evidence). If used, we suggest LEV over PHT/fPHT (weak recommendation, very low quality of evidence) for a short duration (≤ 7 days, weak recommendation, low quality of evidence)."

and:

"There were no significant differences in early or late seizure with longer versus shorter ASM use, though cognitive outcomes and adverse events appear worse with protracted use."

Brain Trauma Foundation (4th ed.) ⚠️: phenytoin recommended (Level IIA) to decrease incidence of early PTS; "Prophylactic use of phenytoin or valproate is not recommended for preventing late post traumatic seizures."

Treatment	dismech pattern
Levetiracetam prophylaxis	`treatment_term` NCIT:C15986 Pharmacotherapy ✅; `therapeutic_agent` CHEBI:6437 levetiracetam ✅; `therapeutic_modality: SMALL_MOLECULE`
Phenytoin / fosphenytoin prophylaxis	NCIT:C15986 ✅ + CHEBI:8107 phenytoin ✅

Chronic pharmacotherapy for established PTE

Standard focal-epilepsy ASMs — levetiracetam, lacosamide, carbamazepine/oxcarbazepine, lamotrigine, valproate, brivaracetam, perampanel, topiramate, zonisamide. No agent is PTE-specific and no head-to-head evidence establishes superiority in this population. All: treatment_term NCIT:C15986 Pharmacotherapy ✅ + a CHEBI therapeutic_agent.

Pharmacogenomics: HLA-B*15:02 (carbamazepine SJS/TEN in Southeast Asian ancestry) and HLA-A*31:01; CYP2C9 poor metabolizers and phenytoin toxicity; UGT1A6/CYP2C9 and valproate levels ⚠️ (PMC5574127). These are ASM-class facts, not PTE-specific — curate them where the drug is curated. (Note: the existing dismech drug_hypersensitivity_scar module is the natural home for the HLA-linked SCAR risk.)

Surgical and interventional

Resective epilepsy surgery (lesionectomy, anterior temporal lobectomy ± amygdalohippocampectomy) for drug-resistant, well-localized PTE. Outcomes in PTE are generally poorer than in mesial temporal sclerosis, because post-traumatic lesions are often multifocal — the injury didn't respect anatomical boundaries. treatment_term NCIT:C15329 Surgical Procedure ✅; therapeutic_modality: SURGERY.
Neuromodulation — vagus nerve stimulation, responsive neurostimulation (RNS), deep brain stimulation (ANT-DBS) for non-resectable/multifocal cases. therapeutic_modality: DEVICE; treatment_term NCIT:C49236 Therapeutic Procedure ✅ (no reliable NCIT device-modality term is inferable — see the CLAUDE.md backfill table).
Laser interstitial thermal therapy (LITT) — ablative alternative.

Supportive and rehabilitative

Cognitive rehabilitation, physical therapy (NCIT:C15302 ✅), occupational and speech therapy, psychiatric management of depression/anxiety, driving-restriction counseling, seizure-safety education. NCIT:C15315 Rehabilitation ✅; NCIT:C15747 Supportive Care ✅. therapeutic_modality: BEHAVIORAL.

Experimental / antiepileptogenic

This is the field's open frontier, and so far it's a graveyard of negative trials:

Agent	Target	Status
Levetiracetam (prevention)	SV2A	Phase 2 safety/feasibility ⚠️ (PMID:22777131, NCT01463033); PTE HR 0.48, p=0.18 — underpowered, not significant
Biperiden (anticholinergic)	Muscarinic	Multicenter RCT, n=312, moderate/severe TBI, 10-day treatment ⚠️ (NCT01048138; Front Neurol 2024). "Data analysis indicated lack of evidence of biperiden for either the incidence of post-traumatic epilepsy or the mortality rate." Negative.
Rapamycin / mTOR inhibitors	mTORC1	Preclinical only. "Rapamycin treatment for one month after TBI decreased the seizure frequency and rate of developing posttraumatic epilepsy during an entire 16 week monitoring session" ⚠️ (PMID:23691153); replicated in rat ⚠️ (PMID:29904395). CHEBI:9168 sirolimus ✅
SJN2511 / ALK5-TGF-β inhibitors	Node 3	Preclinical. "Treatment with SJN2511, a specific ALK5/TGF-β inhibitor, prevents synaptogenesis and epilepsy" ⚠️ (PMID:25836421)
Anakinra / IL-1R antagonists	IL-1β	Preclinical + case-level; no PTE RCT ⚠️
Ceftriaxone	GLT-1/EAAT2 upregulation	Preclinical glutamate modulation ⚠️
Deferoxamine / ferroptosis inhibitors (baicalein)	Iron, ferroptosis	Preclinical, FeCl₃ model ⚠️. CHEBI:4356 desferrioxamine B ✅
Cortical excitability probing (TMS)	Biomarker development	NCT05517954

Register clinical trials in the dismech clinical_trials: block with phase: as the enum form (e.g. PHASE_II) and evidence referencing clinicaltrials:NCT… after just fetch-reference.

13. Prevention

Primary prevention — the only proven lever. Prevent the TBI: helmets (motorcycle, bicycle, sport), seatbelts and airbags, speed control and impaired-driving enforcement, fall prevention in the elderly (vision correction, home hazard reduction, medication review, strength/balance training), firearm safety, combat helmet and body-armor design, child-abuse prevention programs. Every prevented severe TBI removes a 13% five-year epilepsy risk ✅ (PMID:38903174).

Secondary prevention. Aggressive acute neurocritical care to limit secondary injury (ICP control, avoidance of hypoxia/hypotension, hemorrhage evacuation), plus ≤7-day ASM prophylaxis to prevent early seizures ✅ (PMID:38316735). Infection control during the acute admission is a plausible, testable secondary-prevention target given the aRR 1.59 signal ⚠️.

Tertiary prevention. Seizure control to prevent injury, status epilepticus, SUDEP, and further functional decline; ASM adherence support; comorbidity treatment (depression, sleep); driving and occupational safety counseling.

Immunization, genetic screening, genetic counseling, prophylactic surgery: not applicable. (NCIT:C15240 Genetic Counseling ✅ exists but should not be curated for this entry.)

Public health: road safety legislation, alcohol policy, sports concussion protocols and return-to-play rules, elder fall-prevention programs, domestic violence and child-abuse intervention.

14. Other Species / Natural Disease

Species: Homo sapiens (NCBITaxon:9606) — primary. Naturally occurring post-traumatic epilepsy is documented in dogs (Canis lupus familiaris, NCBITaxon:9615) and occasionally cats (Felis catus, NCBITaxon:9685) as "structural epilepsy of traumatic origin" under the IVETF (International Veterinary Epilepsy Task Force) classification ⚠️ — verify NCBITaxon IDs and IVETF citations before curating.
Breed (VBO): no breed-specific predisposition; head trauma is the determinant, not lineage. Not applicable.
Orthologous genes: not applicable — no causal gene. Modifier orthologs (Il1b, Adora1, Gad1, Apoe) exist across mammals but carry no established veterinary PTE association.
OMIA: no PTE entry expected (OMIA covers inherited traits).
Comparative pathology: the core mechanisms — BBB breakdown, albumin/TGF-β astrocyte signaling, iron deposition, interneuron loss, mossy fiber sprouting — are conserved across rodent, canine, and human injured brain, which is why the rodent models retain face validity.
Zoonotic potential / transmission: not applicable.

15. Model Organisms

PTE has arguably the best-developed epileptogenesis model portfolio of any acquired epilepsy — the field can induce the injury on a known day and then watch for months.

Induced (injury) models — the workhorses

Model	Species	Characteristics
Lateral fluid percussion injury (LFPI)	Rat (Sprague-Dawley), mouse	The reference model. "43% to 50% of injured animals developed epilepsy, with a latency period between 7 weeks to 1 year. Mean seizure frequency was 0.3±0.2 seizures per day and mean seizure duration was 113±46 s" ⚠️. Reproduces contusion, subdural/intracerebral hematoma, hippocampal sclerosis, reactive gliosis, mossy fiber sprouting ⚠️. Key refs: Kharatishvili et al., Neuroscience 2006 ⚠️; D'Ambrosio et al., Brain 2004;127:304 ⚠️
Controlled cortical impact (CCI)	Mouse, rat	Highly reproducible mechanics. "Although a large proportion of CCI mice do not develop spontaneous seizures, spontaneous epileptiform spiking occurs suggestive of ongoing epileptogenesis" ⚠️ (Bolkvadze & Pitkänen, J Neurotrauma 2012 ⚠️)
Weight drop / impact acceleration	Rat, mouse	Diffuse injury; lower PTE yield
Blast injury	Rat, mouse, swine	Military-relevant; emerging
Undercut / partial isolation cortex	Rat, cat	Chronic cortical hyperexcitability; mechanistic dissection
Iron/FeCl₃ or hemoglobin cortical injection	Rat, mouse	Isolates the iron/ferroptosis arm (Node 5) ⚠️

The methodological state of the art

EpiBioS4Rx (NINDS Center Without Walls; Finland, Australia, USA) is the field-defining multicenter effort. Its harmonization paper ⚠️ (PMID:38056191) reported the "first demonstration of the feasibility of protocol harmonization for performing powered preclinical multi-center trials for biomarker and therapy discovery of post-traumatic epilepsy." Its Project 1 biomarker study ✅ (PMID:39661396) randomized n=245 adult male Sprague-Dawley rats to LFPI or sham across three sites with 7th-month video-EEG — a scale and rigor almost unheard of in preclinical neuroscience.

Genetic models: conditional/transgenic lines are used as mechanistic probes layered onto an injury model, not as standalone PTE models — e.g. KCC2 (Slc12a5) disruption in parvalbumin interneurons "associated with a decreased seizure threshold and a progressive loss of parvalbumin-positive interneurons" ⚠️, and TGF-β/ALK5 pathway manipulation ⚠️ (PMID:25836421).

Phenotype recapitulation and limitations

Recapitulated well: focal onset seizures; latent period; hippocampal sclerosis and mossy fiber sprouting; interneuron loss; BBB breakdown; reactive gliosis; iron deposition; interictal spikes and HFOs; the severity–incidence gradient.

Not recapitulated / limitations — worth an explicit HUMAN_MODEL_MISMATCH discussion entry: - Rodents are lissencephalic; human contusion patterns depend on gyral/skull geometry. - Most studies use young adult male rodents; human PTE risk peaks in the elderly and in young children, and sex differences are unmodeled. - Seizure frequency in rodent PTE is low (~0.3/day), demanding months of video-EEG and huge n — the main reason preclinical trials have been underpowered. - Absence-like spike-wave discharges in certain rat strains have been mistaken for PTE — a documented confound requiring strain-matched controls ⚠️ (arXiv:1509.05802, "Lack of appropriate controls leads to mistaking absence seizures for post-traumatic epilepsy"). If you take one methodological caution from this section, take that one. - Comorbidity phenotypes (depression, cognition) are measured with instruments of uncertain human correspondence. - Every antiepileptogenic agent that worked in these models has so far failed or gone untested in humans.

Resources

MGI (mouse), RGD (rat), Alliance of Genome Resources, IMPC/KOMP; EpiBioS4Rx data-sharing portal; NINDS Common Data Elements for TBI; FITBIR (Federal Interagency TBI Repository).

Appendix A — Suggested `pathophysiology` node skeleton for the dismech entry

#	Node name	`biological_scale`	Key terms	Downstream
1	Mechanical Brain Injury and Primary Tissue Disruption	TISSUE	UBERON:0000956 ✅	→ 2
2	Blood-Brain Barrier Breakdown and Serum Albumin Extravasation	TISSUE	UBERON:0000120 ✅, CL:0000071 ✅	→ 3, 4, 5
3	Astrocytic Albumin Uptake via TGF-beta/ALK5 Signaling	MOLECULAR	GO:0007179 ✅, GO:0048143 ✅, CL:0000127 ✅	→ 7
4	Neuroinflammatory Amplification	CELLULAR	GO:0150076 ✅, GO:0001774 ✅, CL:0000129 ✅	→ 2 (feed-forward), 6, 9
5	Iron Deposition and Ferroptotic Oxidative Injury	MOLECULAR	GO:0097707 ✅, GO:0006979 ✅, CHEBI:29033 ✅	→ 6
6	Inhibitory Interneuron Loss and Chloride Homeostasis Failure	CELLULAR	CL:0000617 ✅, CHEBI:16865 ✅	→ 9
7	Excitatory Synaptic Reorganization and Aberrant Plasticity	CELLULAR	GO:0050808 ✅, GO:0031929 ✅, GO:0035249 ✅, UBERON:0001885 ✅	→ 9
8	Reactive Gliosis and Perilesional Scar Formation	TISSUE	CL:0000125 ✅	→ 9
9	Neuronal Hyperexcitability and Network Hypersynchrony	CELLULAR	—	→ 10
10	Recurrent Unprovoked Seizures	ORGANISM	HP:0007359 ✅	→ 4, 6 (feedback)

Suggested conforms_to: node 9 → epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance. Suggested treatment target_mechanisms: rapamycin INHIBITS node 7; ALK5 inhibitor INHIBITS node 3; anakinra INHIBITS node 4; deferoxamine INHIBITS node 5. All experimental — pair each with the correct evidence_source: MODEL_ORGANISM.

Appendix B — Citation ledger

Abstract-verified in this session (✅ — quotes above are verbatim, but still run just fetch-reference before committing): PMID:38570704 · PMID:9414327 · PMID:38903174 · PMID:38316735 · PMID:39661396

Needs independent verification before curation (⚠️): PMID:38398011 · PMID:35302046 · PMID:20644150 · PMID:3929158 · PMID:12810485 · PMID:26149793 · PMID:28242442 · PMID:36912749 · PMID:23691153 · PMID:29904395 · PMID:25836421 · PMID:17121744 · PMID:38056191 · PMID:22777131 · PMID:35852600 · PMID:19508123 · PMID:32854584 · Karlander JNNP 2021 (PMID unresolved) · Bolkvadze & Pitkänen J Neurotrauma 2012 (PMID unresolved) · Kharatishvili Neuroscience 2006 (PMID unresolved) · D'Ambrosio Brain 2004 (PMID unresolved) · Neurology 2023 doi:10.1212/WNL.0000000000207183 (PMID unresolved)

Ontology terms verified against local OAK adapters this session: all HP, GO, CL, UBERON, CHEBI, NCIT, and MONDO IDs marked ✅ above. GO:0055072 is obsolete — do not use. No verified CL term for "parvalbumin-positive interneuron" was found; use CL:0000617 with a specific preferred_term. HGNC IDs are not verified and must be checked before use.

Sources: - Insights into epileptogenesis from post-traumatic epilepsy — Nat Rev Neurol 2024 (PMID:38570704) - A population-based study of seizures after traumatic brain injuries — NEJM 1998 (PMID:9414327) - Risk of epilepsy after TBI: nationwide Norwegian matched cohort — Front Neurol 2024 (PMID:38903174) - NCS Guidelines for Seizure Prophylaxis in Moderate-Severe TBI — Neurocrit Care 2024 (PMID:38316735) - Plasma microRNAs as prognostic biomarkers, EpiBioS4Rx Project 1 — Epilepsia 2025 (PMID:39661396) - Epidemiology, Risk Factors, and Biomarkers of PTE — Biomedicines 2024 (PMID:38398011) - Post-Traumatic Epilepsy and Comorbidities — Pharmacol Rev 2022 (PMID:35302046) - Correlates of posttraumatic epilepsy 35 years following combat brain injury — Neurology 2010 (PMID:20644150) - Genetic biomarkers of posttraumatic epilepsy: a systematic review — Seizure 2017 (PMID:28242442) - IL-1β associations with posttraumatic epilepsy development — Epilepsia 2015 (PMID:26149793) - Impact of genetic polymorphisms on epilepsy risk after acute brain injury — Eur J Neurol 2023 (PMID:36912749) - Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling (PMID:25836421) - TGF-beta receptor-mediated albumin uptake into astrocytes in neocortical epileptogenesis (PMID:17121744) - Rapamycin attenuates the development of posttraumatic epilepsy (PMID:23691153) - EpiBioS4Rx preclinical harmonization (PMID:38056191) - Biperiden as antiepileptogenic after TBI — randomized clinical trial, Front Neurol 2024 - Hospital-acquired infections as a risk factor for PTE — registry cohort - Risk and cause of death in post-traumatic epilepsy — J Neurol 2022 (PMID:35852600) - Inflammatory proteins as acute biomarkers of post-traumatic epilepsy - Baicalein suppresses ferroptosis in FeCl₃-induced posttraumatic epileptic seizures - Animal Models of Post-Traumatic Epilepsy — Diagnostics 2020 - Brain Trauma Foundation Guidelines for the Management of Severe TBI, 4th Edition

Ask OpenScientist

OpenScientist Report

Mappings

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Environmental Factors

Diagnosis

Progression

Prevalence

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Post-Traumatic Epilepsy (PTE) — Comprehensive Research Report

1. Disease Information

Overview

Key identifiers

Synonyms (from MeSH D004834 via MONDO) ✅

Information provenance

2. Etiology

Primary causal factor

Risk factors — environmental / injury-related

Risk factors — genetic

Protective factors

Gene–environment interaction

3. Phenotypes

Core seizure phenotypes

Structural / imaging phenotypes

Comorbid / neuropsychiatric phenotypes

Onset, severity, progression, frequency

Quality of life

4. Genetic / Molecular Information

Candidate modifier / susceptibility loci

Epigenetics

Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

The causal chain (trigger → clinical manifestation)

Module conformance opportunities (dismech-specific)

Upstream vs downstream summary

Metabolic, proteomic, transcriptomic

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

Epidemiology

Inheritance

10. Diagnostics

Clinical criteria — the actual diagnostic basis

Electrophysiology

Imaging

Fluid biomarkers

Genetic testing

Screening

11. Outcome / Prognosis

12. Treatment

The central therapeutic fact

Acute prophylaxis (early seizure prevention — NOT antiepileptogenesis)

Chronic pharmacotherapy for established PTE

Surgical and interventional

Supportive and rehabilitative

Experimental / antiepileptogenic

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Induced (injury) models — the workhorses

The methodological state of the art

Phenotype recapitulation and limitations

Resources

Appendix A — Suggested pathophysiology node skeleton for the dismech entry

Appendix B — Citation ledger

Appendix A — Suggested `pathophysiology` node skeleton for the dismech entry